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ABSTRACT 
Pyruvate kinase M2 (PKM2) is a glycolytic enzyme expressed in highly proliferating 
cells. Studies of PKM2 have been focused on its function of promoting cell proliferation in 
cancer cells. Our laboratory previously discovered that extracellular PKM2 released from cancer 
cells promoted angiogenesis by activating endothelial cell proliferation and migration. PKM2 
activated endothelial cells through integrin αvβ3. Angiogenesis and myofibroblast differentiation 
are key processes during wound healing. In this dissertation, I demonstrate that extracellular 
PKM2 released from activated neutrophils promotes angiogenesis and myofibroblast 
differentiation during wound healing. PKM2 activates dermal fibroblasts through integrin αvβ3 
and PI3K signaling pathway. I also claim that extracellular PKM2 plays a role during liver 
fibrosis. PKM2 protects hepatic stellate cells from apoptosis by activating the survival signaling 
pathway.  
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CHAPTER 1 GENERAL BACKGROUND  
1.1 Glycolysis and Pyruvate Kinase 
Glycolysis is a process that consumes glucose to provide energy for cells. It is a 
sequential process with ten metabolic enzyme reactions. One unit of glucose generates two units 
of pyruvate as final product and two units of ATP and NADH as energy resources of glycolysis. 
Glycolysis is regulated by several enzymes which form a complex in the cytosol.  
Glycolysis is divided into two phases, one is preparatory phase and another one is pay-off 
phase. In the preparatory phase, glucose is first converted to glucose-6-phosphate, then to 
fructose-6-phosphate, fructose 1, 6-bisphosphate (FBP), and finally to two units of 
glyceraldehyde 3-phosphate (GADP). ATP is used in the first and the third step as energy 
investment. In the pay-off phase, final product GADP from previous phase is converted into 1, 3-
bisphosphoglycerate, then 3-phosphoglycerate, 2-phosphoglycerate, phosphoenolpyruvate and 
pyruvate as the final product of glycolysis. NADH is generated from the first step and ATP is 
generated from the second and the last step. Glycolysis is regulated by three enzymes during the 
reaction process, hexokinase, phosphofructokinase, and pyruvate kinase.  
Hexokinase is an enzyme functions at the first step of glycolysis. It uses ATP as resource 
to phosphorylate glucose and forms glucose-6-phosphate (G6P). When glucose level increases, 
hexokinase senses the signal and starts to convert glucose to G6P (Bustamante & Pedersen, 
1977). Glucokinase (human hexokinase IV) is one isoform of hexokinases. Due to its unique 
ability that its activity is not affected by the production amount, glucokinase can sustainably 
produce G6P as the storage of energy if enough glucose is provided (Robey & Hay, 2006). 
Phosphofructokinase is an enzyme that catalyzes the irreversible conversion from F6P to FBP. It 
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is regulated by ATP concentration, pH level, PEP level, and also AMP level (Wegener & 
Krause, 2002). 
Pyruvate kinase is an enzyme functions at the last step of glycolysis. It converts 
phosphoenolpyruvate (PEP) to pyruvate by transferring one phosphate group from PEP to ADP 
and generates ATP. Pyruvate kinase is regulated by ATP and alanine as allosteric inhibitors 
(Schulz et al., 1975). FBP acts as an activator for pyruvate kinase that it binds to the pocket on 
pyruvate kinase and alternates its conformation to promote the substrate binding (Ashizawa et 
al., 1991). Pyruvate kinase deficiency shows slow glycolysis and abnormal metabolism. Severe 
metabolism defect is lethal due to extreme low level of ATP (Bowman & Procopio, 1963). 
Pyruvate kinase family contains four isoenzymes with tissue dependent expression, 
pyruvate kinase L (in liver), pyruvate kinase R (in red blood cells), pyruvate kinase M1 (in 
muscle and brain), and pyruvate kinase M2 (in fetal tissue and cancer cells). PKL and PKR are 
products of the same gene PKLR locating on chromosome 1 band q21. PKL is a specific isoform 
of pyruvate kinase existing in liver. It is also found in kidney, small intestine and pancreas. PKL 
is regulated by epinephrine and glucagon through protein kinase A. Upon addition of epinephrine 
and glucagon, activated PKA inhibits the pyruvate kinase activity of PKL by adding 
phosphorylation (Exton & Park, 1969). PKR is another specific isoform of pyruvate kinase in 
erythrocytes. Since erythrocytes are important in oxygen delivering, PKR mutation leads to a 
severe disease called chronic nonspherocytic hemolytic anemia (Valentine et al., 1961). 
PKM1 and PKM2 are products of PKM gene locating on chromosome 15 on band q22 
with different mRNA splicing (Popescu & Cheng, 1990). PKM1 and PKM2 are transcribed from 
the same mRNA with alternatively splicing on exon 9 or exon 10 (Noguchi et al., 1986). They 
have a forty-five amino acids difference between 389 and 433. Compared with PKM1 expressed 
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in normal tissues, PKM2 is mainly expressed in highly proliferative tissues such as cancer cells, 
fetal tissues, and immune cells. A study found that c-Myc in cancer cells upregulates the 
transcription of heterogeneous nuclear ribonuleoprotein (hnRNP) and polypyrimidine tract 
binding protein 1 (PTBP1) to promote inclusion of exon 10 during pre-mRNA splicing in order 
to favors cancer cell metabolism (David et al., 2010). The expression of PKM2 is first occurred 
during embryonic development, and then it switches to PKM1, PKL, or PKR after fetal 
development. During cancer progression, expression of PKM2 is switched back (M. Chen et al., 
2010). The level of PKM2 expression is correlated with cancer progression and metastasis. The 
pyruvate kinase activity of PKM2 is lower than PKM1 even with the association of FBP, which 
is the allosteric activator of pyruvate kinase.  
1.2 Pyruvate Kinase M2  
1.2.1 Pyruvate kinase M2 structure and regulation  
PKM1 and PKM2 share more than 95% identity in the amino acid sequences because of 
the one exon splicing difference. PKM1 forms a tetramer in its native structure. Each monomer 
consists of A, B, C, and N four domains. On the other hand, PKM2 is found to have two native 
forms. One is the same as PKM1 as a tetramer and another one is a dimer (Dombrauckas et al., 
2005). The tetrameric conformation of pyruvate kinase has higher binding affinity to 
phosphoenolpyruvate (PEP), compared with the dimeric form. Therefore, the pyruvate kinase 
activity of PKM1 is higher than that of tetrameric PKM2, giving the high affinity of PKM1 to 
substrate PEP. In the native structure of PKM2, different amino acid residues locate at the 
interface of dimer-dimer PKM2.  
As a key kinase in glycolysis, PKM2 is regulated by several factors. FBP, one of the key 
activators PKM2, is the intermediate in glycolysis pathway. It is reported that FBP activates the 
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association of PKM2 monomer to form tetramer in vitro. After binding to FBP, the active site of 
PKM2 is partially closed as a result of the conformational change induced by FBP binding. 
PKM2 is also regulated by different phosphorylations. A report found that proviral insertion in 
murine lymphomas 2 (PIM2) induces the expression of PKM2 by direct phosphorylation on Thr 
454. This threonine residue of PKM2 is critical in cancer cells. Mutation of this residue leads to 
glycolysis defect and proliferation reduction (Yu et al., 2013). A study revealed that epidermal 
growth factor receptor (EGFR)-activated extracellular signal-regulated kinase 2 (ERK2) interacts 
with Ile 429 and Leu 431 of PKM2 and phosphorylates Ser 37 to promote nuclear translocation 
of PKM2, which consequently stimulates c-Myc expression. The expression of c-Myc positively 
feedback facilitates the PTB-dependent PKM2 expression (W. Yang, Zheng, et al., 2012). 
Another study claims that in order to promote Warburg effect and tumor growth, fibroblast 
growth factor receptor type 1 (FGFR1), a receptor tyrosine kinase, phosphorylates PKM2 at Tyr 
105 to inhibit its tetramer formation through disrupting FBP binding (Hitosugi et al., 2009). 
PKM2 is also found to bind phosphotyrosine peptide to promote cancer cell proliferation. The 
binding of phosphotyrosine peptides to PKM2 causes the dissociation of FBP which leads to 
inhibition of PKM2 activity (Christofk, Vander Heiden, Wu, et al., 2008). In addition, PKM2 
mutations have been detected in many disease situations. As an example, PKM2 mutations 
(H391Y and K422R) are found in Bloom Syndrome (BS) condition. Co-expression of mutants 
H391Y and K422R in cancer cells significantly increased aggressive cancer metabolism, and 
tumorigenic potential (Akhtar et al., 2009; Gupta et al., 2010). 
1.2.2 Location of pyruvate kinase M2 
As a glycolytic enzyme, PKM2 is first discovered in glycolytic enzyme complex. To help 
the conversion from PEP to pyruvate and ATP generation, PKM2 locates in the cytosol and 
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catalyze the last step of glycolysis. After that, pyruvate is transported to mitochondria for the 
following catalysis.  
PKM2 is also found in cell nucleus in numbers of studies. A study showed that 
interleukin-3 stimulates the nuclear translocation of PKM2 by Jak2 activation, and then promotes 
cell proliferation (Hoshino et al., 2007). JMJD5 is induced by hypoxia to stimulate cell 
proliferation. Under hypoxia, upregulated JMJD5 binds to PKM2 at the dimer-dimer interface 
and inhibits its pyruvate kinase activity. The binding at PKM2 dimer-dimer interface disrupts the 
nuclear translocation of PKM2 and promotes hypoxia-inducible factor 1-α (HIF-1-α) mediated 
transactivation (Wang et al., 2014). Yang et al. reported that PKM2 presents in cell nucleus to 
phosphorylate histone H3 at Thr 11 after EGF receptor activation (W. Yang, Xia, Hawke, et al., 
2012). Our laboratory previously showed that dimeric PKM2 can translocate into cell nucleus. 
Nuclear PKM2 activates the transcription activity of MEK5 via phosphorylating stat3 at Tyr 105 
(Gao et al., 2012). Compared with activation of proliferation, PKM2 can also translocate into cell 
nucleus to induce program cell death (Stetak et al., 2007). 
PKM2 has been found extracellularly in several pathological conditions. PKM2 is used as 
a serum diagnostic marker in colorectal cancer, lung cancer, gastric cancer, and kidney cancer 
(Peng et al., 2011). PKM2 also exists in the stool sample of various cancer patients (Kopylov et 
al., 2014). One study claimed that PKM2 is secreted from colon cancer cells and is able to 
promote colon cancer cell migration (P. Yang et al., 2014). Our lab found that PKM2 is released 
from cancer cells, and extracellular PKM2 can activate endothelial cell migration and 
attachment. The level of extracellular PKM2 is also correlated with the progression of severe 
immune diseases. PKM2 is used as serum marker for inflammatory bowel disease (IBD) (Jeffery 
et al., 2009). Faecal PKM2 is reported to be used as noninvasive marker for ileal pouch 
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inflammation (Johnson et al., 2009). Recently, a study discovered that PKM2 level is increased 
after retinal rupture laser injury (Paulus et al., 2015). 
1.3 Functions of PKM2 
PKM2 is expressed during embryonic development. The function of PKM2 in fetal tissue 
is still not clear. PKM2 interacts with Oct-4, a key transcription factor in embryonic stem cells, 
to promote the transcription activity of Oct-4. The binding of Oct-4 to its target requires PKM2, 
possibly C terminal domain of PKM2 (Lee et al., 2008). PKM2 is also expressed in 
hematopoietic stem cells. Depletion of PKM2 disadvantages disease development of myeloid 
leukemia in mouse model (Zhu et al., 2014). 
After fetal development, PKM2 is replaced by other three isozymes, PKM1, PKR, or 
PKL. Expression of PKM2 occurs during cancer progression. PKM2 is expressed in all cancer 
cells and also some highly proliferating cells, such as immune cells. All pyruvate kinase 
isoenzymes form similar tetramer. The pyruvate kinase activity of PKM2 is lower compared with 
other isoenzymes because of the low PEP binding affinity of dimer, which can be enhanced by 
FBP interaction.  
PKM2 functions in several physiological and pathological conditions in addition to its 
pyruvate kinase activity in glycolysis. One well-known role of PKM2 in cancer cells is 
promoting Warburg effect, which is one of the common features among highly proliferative 
cells. As an example, cancer cells prefer to use glycolysis to produce energy but not oxidative 
phosphorylation even under the aerobic environment. One explanation of Warburg effect is that 
the pyruvate kinase activity of PKM2 is reduced by the conversion from tetramer to dimer. As a 
result, the glycolysis process becomes slower at the step of converting PEP to pyruvate due to 
the low pyruvate kinase activity of dimeric PKM2. Consequently, the upstream glycolytic 
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intermediates are accumulated and converted to the products which are needed for cell 
proliferation, such as phospholipids, amino acids and nucleic acids. Therefore, the highly 
proliferative cells under Warburg effect condition tend to reduce their aerobic respiration and 
focus on the proliferation task (Christofk, Vander Heiden, Harris, et al., 2008; Ferguson & 
Rathmell, 2008; W. Yang & Lu, 2013). 
PKM2 is also found to act as a sensor to detect insufficiency of glucose. To accomplish 
the goal, PKM2 shifts glycolysis to glutaminolysis for ATP production by inactivating itself, 
which rescues the cells from glucose starvation induced cell apoptosis. PKM2 involves in the 
Raf kinase pathway that α-Raf can activate PKM2 to promote cell proliferation (Le Mellay et al., 
2002; Mazurek et al., 2007). PKM2 also plays a role in the immunological response through 
interacting with suppressor of cytokine signaling 3 (SOCS3) and upregulating ATP production 
(Z. Zhang et al., 2010). Recently, a group reported that PKM2 translocates into cell nucleus and 
regulates gene transcription through interacting with specific gene transcription regulators such 
as hypoxia-inducible factors (HIF1) and signal transducer and activator of transcription 3 
(STAT3) (W. Yang, Xia, Cao, et al., 2012). 
Another characteristic of PKM2 is that it can be secreted by cancer cells. There are high 
levels of PKM2 circulating in the blood stream of cancer patients. Serum PKM2 and stool PKM2 
are used as cancer markers to prognose various types of cancers. In our laboratory, we 
demonstrated that PKM2 was released from cancer cells and human embryonic kidney (HEK) 
293 cells. PKM2 in blood circulation promoted tumor growth through stimulation of 
angiogenesis. We found that in xenograft tumor mouse model neutralization of PKM2 using 
polyclonal antibody against full length PKM2 inhibited the tumor growth compared with the pre-
immune IgG as the control. We also found that addition of PKM2 to blood circulation can 
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promote tumor growth through stimulating angiogenesis. In vitro tube formation assay showed 
that the PKM2 treated human umbilical vein endothelial cells (HUVECs) had elevated tube 
density and increased tube sprouts number compared with the control cells, suggesting the role 
of PKM2 in stimulating angiogenesis. In addition, migration and attachment assays indicated that 
extracellular PKM2 promoted endothelial cell migration and attachment. We also found that 
integrin αvβ3 was the cell surface target of endothelial cells for PKM2 activated migration, 
attachment, and tube formation (L. Li et al., 2014). 
1.4 Wound Healing 
1.4.1 Wound healing process 
Wound healing is a complicated process that organs and tissues repair themselves after 
injury. This process consists of numbers of phases in sequence. Wound healing process is mainly 
divided into four stages: hemostasis, inflammation, proliferation, and maturation.  Hemostasis 
happens right after wound induction. Since blood vessel is broken caused by the injury, platelets 
move to the broken vessels and aggregate. The main function of platelets at wound site is to clot 
blood vessel in order to stop bleeding. To induce aggregation, platelets express glycoproteins on 
the plasma membrane to enhance cell-cell attachment. Platelets secrete large amounts of 
extracellular matrix, for example fibrin and fibronectin which cross-link together to seal the 
broken blood vessels. In addition, platelets also secrete several cytokines and grow factors, 
which recruit different types of immune cells to the wound site (Versteeg et al., 2013). 
Hemostasis is active for several minutes at the beginning of wound healing. The second 
stage is called inflammation that different kinds of immune cells infiltrate into the wound site. 
Among them, the first one is polymorphonuclear neutrophil. Neutrophils are recruited by 
fibronectin and other growth factors right after hemostasis. In human, neutrophils start to 
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accumulate hours after wound induction, and reach the peak of population at about two days. 
Neutrophils kill bacteria by generating free radicals and extracellular traps, and secrete proteases 
to clean dead cell debris (Segal, 2005). Neutrophils also release multiple growth factors and 
cytokines functioning to trigger the next proliferation stage (Kolaczkowska & Kubes, 2013). The 
population of neutrophils declines two or three days after wound induction (Kim et al., 2008). 
Apoptotic neutrophils are phagocytized by macrophages, the second population of immune cells 
coming to the wound sites after neutrophils. Macrophages cleanse the wound site by 
phagocytizing other immune cells, bacteria, and cell debris (Newton et al., 2004). Another 
function of macrophage is to facilitate wound healing. After arriving at the wound site and being 
activated, macrophages secrete several cytokines and growth factors to stimulate angiogenesis 
and granulation tissue growth (Majno, 1998). Macrophages also play a role of anti-angiogenesis 
and anti-fibrosis at the late stage of wound repair (Leibovich & Wiseman, 1988). 
Towards the end of inflammatory stage, proliferation stage begins that endothelial cells 
and fibroblasts are attracted to the wound site under the effect of chemokines and cytokines 
secreted by immune cells. Proliferation phase can be divided into two parallel sub phases: 
angiogenesis and granulation tissue formation. Angiogenesis is the process that new blood 
vessels grow from the pre-existing vessels. It occurs first in order to provide nutrition supply for 
proliferation stage. Endothelial cells are attracted by chemoattractant and sprouts out to form 
tube structures (Tonnesen et al., 2000). Hypoxia is a factor to stimulate endothelial cell migration 
and proliferation that the activated endothelial cells tend to migrate towards the area lack of 
oxygen. Endothelial cells also release proteases to digest extracellular matrix in order to migrate 
to destination.  Granulation tissue formation happens simultaneously along with angiogenesis. 
The main source of granulation tissue is fibroblast. Quiescent fibroblasts from adjacent tissue are 
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activated by growth factors released from immune cells. They migrate to the wound site and 
proliferate rapidly to form the granulation tissue to seal the wound area (Bainbridge, 2013). 
While fibroblasts and capillary vessels filling the wound site, fibroblasts also differentiate to 
myofibroblasts to help the wound repair. Myofibroblasts secrete large amounts of collagen to 
help building up and strengthening granulation tissue. Myofibroblasts also facilitate the 
contraction of wound by increase contractile ability of granulation tissue (Grinnell, 1994). 
Epithelialization happens throughout inflammation and proliferation stage. Keratinocytes, with 
the help of granulation tissue, migrate towards wound center to cover the outside wound area 
(Pastar et al., 2014). 
The last phase of wound healing is maturation. After wound site is filled up by 
granulation tissue, the secretion of collagen is slowed and type III collagen is gradually replaced 
by type I collagen, the original collagen in skin. The disordered collagen matrix is rearranged 
and cross-linked to form network. Granulation tissue in wound site is converted to the original 
skin tissue. Maturation stage is the longest stage in wound healing, which may take several 
months depending on the wound size (Teller & White, 2009). 
1.4.2 Neutrophil infiltration 
Neutrophils are differentiated from myeloid progenitor cells in bone marrow. Inactivated 
neutrophils can circulate in the blood flow for several days (Witko-Sarsat et al., 2000). After 
activation, neutrophils adhere to blood vessel and infiltrate through in order to migrate toward 
the wound tissue (Gonzalez et al., 2007). Activated neutrophils are attracted by the gradient of 
cytokines, such as IL-8 and IFN-γ to the wound site (Ellis & Beaman, 2004; Hammond et al., 
1995). Neutrophils act as a double-edged sword during wound repair. If neutrophils are over-
activated or neutrophil infiltration is not controlled, tissues will be damaged by the proteases 
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released from neutrophils. However, if neutrophils are not present at wound site, spreading of 
bacteria will cause infection that strongly slows wound healing time (Smith, 1994). Neutrophils 
phagocytize bacteria at the infection site. They release different types of protein through a 
process called degranulation. Four types of granules, azurophilic granules (primary granules), 
specific granules (secondary granules), tertiary granules, and secretory vesicles are stored in 
neutrophils upon activation and released in sequential order after arrival at the infection site. The 
primary granules contain most toxic mediators, such as elastase, cathepsins, and defensins. The 
secondary granules store lactoferrin and metrix metalloprotease 9 (MMP9) (Borregaard & 
Cowland, 1997). Degranulation of neutrophils is activated by fMLP or IL-8 induced GPCR 
activation, which sequentially triggers several signal pathways including Rho guanosine 
triphosphatase Rac2, β-arrestins, and src family of tyrosine kinases (C. X. Chen et al., 2011). The 
activated granules translocate to plasma membrane and fuse with it to release the contents (Lacy, 
2006). Activated neutrophils can also release fragments of DNA which contains several 
proteases to kill bacteria. The released DNA fragments form web-like structure to trap the 
microbes (Brinkmann et al., 2004). 
PKM2 is expressed in neutrophils. Activated neutrophils in inflammation diseases had 
enhanced pyruvate kinase expression and activity. Several reports have shown that PKM2 could 
be used as serum or faecal markers in various inflammatory diseases. For example, pouch 
inflammation had increased PKM2 level in stool samples that could be used as indicator. 
Mycosis fungoides upregulated PKM2 in blood that plasma PKM2 was considered as potential 
marker (Hapa et al., 2011). A recent proteomic study suggested that PKM2 represented in human 
neutrophil granules, which provides good evidence of PKM2 release from neutrophils in 
inflammatory diseases (Lominadze et al., 2005). 
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1.4.3 Angiogenesis 
Angiogenesis is the process of generating new blood vessels from existing ones. It is a 
sequential and complicated process. Several different types of cells and growth factors are 
involved. To start angiogenesis, growth factors and cytokines are released from cancer cells, 
embryonic cells fibroblasts, and immune cells. The factors and cytokines then activate the 
endothelial cells on the pre-existing vessels through interacting with specific receptors locating 
on the cell membrane. Meanwhile, mural cells such as smooth muscle cells and pericytes 
dissociate from the blood vessels to leave space for endothelial cells to migrate. The activated 
endothelial cells proliferate and sprout out towards the tumor or wound areas to form new vessel 
tubes which will be stabilized by mural cells afterwards. During the angiogenesis process, 
endothelial cells also release protease to degrade extracellular matrix in favor of their migration 
(Risau, 1997). 
Angiogenesis is regulated by a variety of pro-angiogenic and anti-angiogenic factors. In 
quiescent situation, the two types of factors are balanced to prevent unnecessary angiogenic 
effect. When angiogenesis is needed for embryonic development, wound recovering or cancer 
progression, pro-angiogenic factors such as vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), and (platelet-derived growth factor) PDGF, are upregulated that 
can cause balance to lean towards pro-angiogenic side, which will initiate the angiogenesis 
process (J. Li et al., 2003). 
Angiogenesis involves in several physiological and pathological processes, such as 
wound healing, tumor growth and metastasis. After blood clot by platelets and clean of wound 
site by immune cells, angiogenesis takes place at early stage of proliferation and together with 
fibrogenesis to construct granulation tissues to support wound healing process. Capillary vessels 
13 
built through angiogenesis can provide nutrient to fibroblast proliferation and maturation. FGF2 
is a 155 amino acids length heparin-binding protein belongs to FGFs family. It regulates 
angiogenesis by stimulating proliferation and migration of endothelial cells, smooth muscle cells 
and fibroblasts (Powers et al., 2000). FGF2 is widely expressed in the wound area and FGF2 null 
mice show delayed healing and thicker scabs when compared with wild-type mice. FGF2 may 
play a major role in promoting angiogenesis and granulation tissue formation during wound 
healing (Ortega et al., 1998). It is important to have angiogenesis to “feed” granulation tissues 
and assist the wound recovering steps. However, the angiogenic effects cannot be overstimulated 
at later stage of wound healing. It needs to be shut down for the remodeling process.  
In pathological conditions, e.g. cancer progression, angiogenesis functions in two 
processes. In process of tumor growth, cancer cells need angiogenesis to recruit blood vessels for 
oxygen and nutrient supply. Solid tumor cannot grow beyond 1 mm
3
 without the support of 
blood vessels. To favor tumor growth, cancer cells generate various pro-angiogenic factors to 
promote angiogenesis. These pro-angiogenic factors stimulate the angiogenesis through 
activating endothelial cell proliferation and migration, and also mural cell dissociation. The 
newly divided endothelial cells migrate to the tumor site and form the vessel tubes. Inside the 
tumor tissues, blood vessel formation is not well regulated due to genetic errors of cancer cells 
and tumor endothelial cells. The disorganization of tumor blood vessel reduces the anti-therapy 
efficiency because unregulated vessel network causes resistance to blood flow, which reduces 
delivery to all cancer cells. Unregulated vessels also generate local hypoxia in tumor which 
continuously activates angiogenesis. In addition, angiogenesis plays an important role in cancer 
metastasis. At the late stage of cancer progression, cancer cells gain ability to penetrate to 
surrounding tissues to form secondary tumors, or even to invade into the blood vessels and 
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circulate with the blood flow to other tissues and organs. Newly formed tumors can stimulate 
neovascularization to recruit nutrient supply for rapid growth. Studying angiogenesis in cancer 
progression can provide targets for anti-angiogenic therapy to restrain tumor growth in early 
stage and prevent metastasis (Bergers & Benjamin, 2003; Weis & Cheresh, 2011). 
1.4.4 Myofibroblast differentiation 
Fibroblasts differentiate to myofibroblasts during wound healing and tissue repair. The 
differentiated myofibroblasts gain high contractile ability to help wound healing process. After 
the wound is healed, myofibroblasts undergo apoptosis to prevent excessive stress in the tissue. 
If myofibroblast differentiation is not well controlled, it causes fibrotic diseases and supportive 
matrix in tumor growth (Eckes et al., 2000). 
The differentiation from fibroblast to myofibroblast is divided into two main steps. The 
first step is from fibroblast to proto-myofibroblast. Fibroblasts are recruited to the wound site 
and acquire minor stress fibers by influence of mechanical force. The second step is from proto-
myofibroblast to differentiate myofibroblast. Proto-myofibroblasts are activated by growth 
factors such as TGFβ to stimulate the expression of α-SMA. α-SMA binds with stress fiber 
bundles to further increase contractile activity of myofibroblasts (Hinz et al., 2001; Masur et al., 
1996). 
Myofibroblasts have various origins other than fibroblasts. Fibroblasts are the major 
resources of myofibroblasts which are attracted to the inflammation site during wound repair. 
Pericytes and smooth muscle cells from blood vessels can also be transformed into 
myofibroblasts. Fibrocytes generated from bone marrow are found to be another important origin 
in the wound case. It is also discovered that fibrocytes take place in fibrosis and tumors to play a 
role of myofibroblast differentiation (Baum & Duffy, 2011). 
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To identify myofibroblasts, three structural features are important: stress fiber bundles, 
high attachment force, and increase cell-cell interaction. α-SMA is the most commonly used 
myofibroblast marker. However, α-SMA is also expressed in other cells such as smooth muscle 
cells. In addition to the stress features and α-SMA expression in myofibroblasts, induced 
extracellular matrix is found in differentiated myofibroblasts. Collagens type I, III, IV, and V are 
secreted by differentiated myofibroblasts to build up the matrix network surrounding 
myofibroblasts and strengthen the tissue contractile (Hinz, 2007). 
The major pathway to activate myofibroblast differentiation is TGFβ-Smad pathway. 
TGFβ interacts with to activate TGFβ receptor type II which subsequently recruits TGFβ 
receptor type I. Association of TGFβ receptor heterodimer activates its serine/tyrosine kinase 
activity, and phosphorylates Smad2/Smad3. Phosphorylated Smad2/Smad3 binds to Smad4 and 
translocates into the nucleus to activate α-SMA transcription through interacting with α-SMA 
promoters (Engler et al., 2011; Midgley et al., 2013). A few of Smad independent pathway has 
been revealed under activation of TGFβ. PI3K is activated by TGFβ signal and transfers the 
signal to downstream p21-activated kinase-2 (PAK2), which induces the expression of α-SMA to 
promote myofibroblast differentiation (Wilkes et al., 2005; Wilkes et al., 2003). Connective 
tissue growth factor and gelectin-3 are cooperatively worked with TGFβ in some circumstances. 
Integrin is also found to cooperate with TGFβ receptor in the TGFβ-Smad signal pathway (Ding 
et al., 2008; Thannickal et al., 2003). IL-6 and nerve growth factor are discovered to activate 
myofibroblast differentiation without the presence of TGFβ, but inhibition of TGFβ signal is not 
ruled out in the study (Gallucci et al., 2006). Thus, the independent of TGFβ signal pathway may 
still need the downstream of TGFβ pathway.  
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1.4.5 From immune response to proliferation 
Neutrophils and macrophages are recruited to wound site after injury. They clean bacteria 
and damaged cell debris to provide a clean wound for closure. Another important function of 
immune cells is to initiate and promote proliferation, including angiogenesis, fibrogenesis and re-
epithelialization. Neutrophils and macrophages secrete numbers of growth factors and cytokines 
to activate endothelial cells and fibroblasts (Barrientos et al., 2008). 
Macrophage is considered the major resource of growth factors and cytokines to activate 
angiogenesis and fibrogenesis. TGFβ is released from macrophage and activates both 
angiogenesis and fibrogenesis during proliferation stage. A chicken chorioallantoic membrane 
(CAM) model showed that TGFβ-1 induced the formation of large blood vessels and also 
increased fibroblast density. TGFβ-1 activates both proliferation and migration ability of 
endothelial cells (E. Y. Yang & Moses, 1990). A study revealed that tumor necrosis factor α 
(TNFα) secreted from activated macrophages blood vessel formation in a rat cornea model. 
TNFα stimulated chemotaxis of endothelial cells and enhanced tube formation  (Leibovich et al., 
1987). Granulocyte/macrophage colony-stimulating factor (GM-CSF) is another growth factor 
secreted by macrophages. GM-CSF is found to induce early stage of endothelial tube formation 
and late stage of new vessel maturation by regulating VEGF and Ang-Tie expressions (Zhao et 
al., 2014). 
 Functional study of neutrophil during wound repair is mainly focused on anti-
microorganism. A group claimed that activated neutrophils increased VEGF expression and 
released VEGF to promote angiogenesis (Gong & Koh, 2010). IL-1 and IL-6 are also correlated 
with proliferation stage during wound healing. IL-1α and IL-1β upregulated the expression of 
keratinocyte growth factor (KGF) in fibroblasts (Tang & Gilchrest, 1996). IL-6 deficient and IL-
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6 antibody treated mice showed delayed wound closure (X. L. Zhang et al., 2005). In addition, 
infiltrating neutrophils functioned in tumorigenesis to switch the pro-angiogenesis (Nozawa et 
al., 2006). Given the fact that neutrophils arrive at wound site in the early inflammation, they 
may play a role of initiating angiogenesis and fibrogenesis during wound repair. 
1.4.6 Treatment of wound 
For treatment of wound to facilitate repair, different aspects are considered. Collagen 
dressings, hydrogels, and growth factors are used to enhance epithelialization. Some drugs are 
used to enhance granulation tissue formation. To prevent infection, antimicrobials are always 
combined with other drugs in severe wound cases. Several growth factors are released during 
wound healing to facilitate the process. Thus, applications of growth factors are proved to have 
positive effect on wound healing (Falanga, 2004). Topical application of EGF was first found to 
enhance wound healing (Brown et al., 1989). PDGF is also approved by FDA for treatment of 
wound (Pierce et al., 1991). However, the application of growth factors is not recommended in 
clinical treatment. Different stages of wound are well organized in a sequential order. For each 
reaction, it needs to be switched on and off at certain time point. Excessive application of growth 
factors may cause prolonged angiogenesis and granulation tissue growth which will inhibit 
wound healing by postponing the maturation process.  
1.5 Liver fibrosis and cirrhosis 
1.5.1 Introduction of liver fibrosis and cirrhosis 
Liver fibrosis is characterized by the accumulation of extracellular matrix, especially 
collagen in liver. Chronic liver damages induced by alcohol abuse, hepatitis virus, and obesity 
are the main causes of liver fibrosis. The accumulated extracellular matrix proteins disrupt the 
architecture of liver tissue by forming scar-like network. Advanced liver fibrosis leads to 
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cirrhosis which is defined as separation of the hepatocyte nodules by scar tissue. In the late stage 
of cirrhosis, scar tissue gradually replaces original liver structure, and finally causes the block of 
portal blood flow, and portal hypertension (Bataller & Brenner, 2005; Friedman, 2003). 
Liver fibrosis is not easy for diagnosis until development of late stage cirrhosis. Chronic 
liver damage takes several years to progress of liver fibrosis to cirrhosis. Cirrhosis is often 
correlated with other complications such as ascites, esophageal variceal bleeding, and 
hepatocellular carcinoma. Biopsy is the standard method for diagnosis of liver fibrosis. Histology 
staining of biopsy can be graded by pathologist in order to identify the stage of liver fibrosis. 
Given that collagen expression is the key feature of liver fibrosis, Sirius red staining of biopsy is 
another convenient method to identify fibrotic status. However, biopsy is an invasive method 
with high error.  One time biopsy examination is not suitable for detection of progression of 
fibrosis (Thampanitchawong & Piratvisuth, 1999). Serum markers of fibrosis are used as a 
noninvasive detection for liver fibrosis. Liver fibrosis patients show high serum level of 
aminotransferase, total proteins, collagen, and TIMP-1 (Arthur, 2000). Although serum marker 
screening is not invasive method compared with biopsy, it is still not able to identify the 
progression of liver fibrosis. Imaging techniques, such as ultrasonography, computed 
tomography, and MRI, are also applied in the diagnosis of liver fibrosis due to their 
noninvasiveness and good vitalization (Hirata et al., 2001; Popper & Uenfriend, 1970). 
1.5.2 Pathogenesis of liver fibrosis 
Liver fibrosis starts with inflammation caused by hepatic injury. In regular case, 
fibrogenesis starts after hepatic injury and ends when injury is healed, so the inflammatory 
response is stopped afterwards. However, in the fibrosis case, the hepatic injury persists 
overtime, which leads to prolonged inflammation and subsequent fibrogenesis. Ultimately, 
19 
hepatocytes are replaced with various ECM and eventually the liver fails to heal back. During the 
progression of liver fibrosis, ECM accumulation first occurs around portal tracts or 
perisinusoidal areas, then elongates to form bridges between the portal tracts, and finally expands 
to large area and disrupts liver structure. This is so called frank cirrhosis. Several ECM are 
involved in liver fibrosis, including collagens (type I, III, and IV), fibronectin, elastin, laminin, 
and proteoglycans. The accumulation of ECM is caused by inhibition of protease such as MMPs, 
and activation of TIMPs, specific inhibitors of MMPs.  
Hepatic stellate cells (HSCs) are the main player in liver fibrosis development and 
progression. In the normal liver, quiescent HSCs reside in liver and function to store vitamin A. 
In fibrotic liver, HSCs are activated by different types of factors and migrate to the injury site to 
secrete larger amounts of ECM. Platelets are the first cells coming to the injury site. They release 
PDGF, TGFβ, and also EGF to activate HSCs including proliferation, migration and 
differentiation (Marra, 1999). Activated Kupffer cells at the fibrotic site also secrete large 
amounts of cytokines to stimulate HSCs (Naito et al., 2004). Since hepatic injury results in 
inflammatory response, infiltrated leukocytes also join with Kupffer cells to activate HSCs. 
Neutrophils produce ROS to stimulate the collagen synthesis of HSCs. It was found that co-
culture of neutrophils with HSCs induced collagen production up to three-fold in vitro.  In 
addition, several interleukins released by Th1 and Th2 lymphocytes also play a role in HSCs 
activation and differentiation. Activated HSCs acquire several behaviors to favor fibrogenesis. 
Activated HSCs are attracted by chemoattractants, and their migration activity is upregulated. 
ECM production is increased in the activated HSCs. Activation transforms HSCs to 
myofibroblasts under stimulation of TGFβ. Induction of collagen expression is the most typical 
feature in TGFβ activation of HSCs. On the other hand, ECM degradation is another important 
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phenomenon of activation of HSCs. MMPs secreted by HSCs is first upregulated in early stage 
of fibrosis to degrade pre-existing ECMs. As long as the fibrosis goes on, the activity of MMPs 
is reduced by increase tissue levels of TIMP. Increase in TIMP prevents MMP from degrading 
the newly formed ECM network, and maintains progression of fibrosis. Activated HSCs also 
acquire high contractile ability due to expression of α-SMA and formation of fiber bundles. 
Endthelin-1 is another activator to stimulate contractile ability besides TGFβ (Sato et al., 2003). 
1.5.3 Reverse of liver fibrosis 
Liver fibrosis and cirrhosis was considered as “irreversible” for many years. However, 
more and more experiments and clinical evidences have shown that liver fibrosis and cirrhosis 
are reversible. One of the most critical keys in those discoveries is the apoptosis of activated 
HSC. One group showed that rats with liver fibrosis induced by CCl4 were able to recover by 
removing activated HSCs through apoptosis. Both generator of new ECM and protector of ECM 
degradation were eliminated by removal of activated HSCs. The group followed tests with 
another model, bile duct ligation, and found that the activated HSCs apoptosis was significantly 
enhanced during recovery stage (Benyon & Iredale, 2000; Elsharkawy et al., 2005). 
The survival and apoptosis of HSCs is regulated by several mediators. ECM is the main 
source to support growth and migration of HSCs. One study suggested that collagen type I 
played a role in maintaining the activation of HSCs and mutation of collagen type I resulted in 
activated HSCs apoptosis (Bataller & Brenner, 2001). Integrin is also critical for the survival of 
HSC. The activated HSCs express integrin αvβ3 on cell membrane. Knockdown integrin αvβ3 
by RNAi or inhibition by antibody against the integrin was found to induce HSCs apoptosis 
(Iwamoto et al., 1999; Zhou et al., 2004). Several growth factors have been shown to inhibit 
HSCs proliferation or induce HSCs apoptosis. Nerve growth factor (NGF) is a growth factor 
21 
secreted by hepatocytes. Treatment of activated HSCs by NGF leads to inhibition of 
proliferation. Fas and FasL have been studied for the induction of HSCs apoptosis (Trim et al., 
2000). The activated HSCs have increased expression of both Fas and FasL. Treatment of 
activated HSCs with FasL or Fas antibody causes apoptosis in vitro. TNF-related apoptosis –
inducing ligand (TRAIL) is another apoptotic mediating factor of activated HSC. The TRAIL 
and TRAIL receptor expression is also upregulated in the activated HSCs in the similar manner 
as of Fas and FasL.  TRAIL and TRAIL receptor agonists can induce HSCs apoptosis in vitro 
(Anan et al., 2006). Nuclear factor kappa B (NF-κB), a well-studied DNA transcription regulator 
in several inflammatory events, is involved in the protection of activated HSCs from apoptosis 
by upregulating several anti-apoptotic factors including, TRAF-1, TRAF-2, c-IAP1 and c-IAP2. 
A study suggested that treatment of NGF induced apoptosis of HSCs and also reduced the 
transcriptional activity of NF-κB (Luedde & Schwabe, 2011; Qu et al., 2007; Takahra et al., 
2004). In summary, liver fibrosis and cirrhosis have potential to be reversible. Therapy targeting 
activated HSCs apoptosis is proved to be a promising method for treatment of liver fibrosis and 
cirrhosis.  
1.6 Rational and Aims 
Previous studies from our laboratory demonstrated that extracellular PKM2 released from 
cancer cells promoted tumor growth through activating angiogenesis. PKM2 promoted tumor 
angiogenesis by stimulating endothelial cell proliferation, migration, and adhesion. Angiogenesis 
plays an important role in proliferation stage of wound healing. It connects granulation tissue 
formation with inflammatory response. Cytokines and growth factors are released from immune 
cells during inflammation stage, and then activate angiogenesis. The newly formed vessels 
provide blood flow and nutrient supply for growth of granulation tissue. Given that PKM2 is a 
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protein expressed and secreted in both cancer cells and neutrophils, and the facts that cancer 
progression and wound healing share surprisingly high similarity in many features, it is very 
reasonable to hypothesize that PKM2 may play a similar role of promoting angiogenesis in 
wound healing. Therefore, we hypothesize that extracellular PKM2 released by neutrophils 
promotes angiogenesis to facilitate wound healing process. 
In our laboratory, we found that extracellular PKM2 activated endothelial cells via 
integrin αvβ3. Fibroblasts upon differentiation have increased expression of integrin αvβ3. 
Integrin αvβ3 involves in the myofibroblast differentiation. Given the fact that fibroblasts are the 
main source in proliferation stage, it is very likely that extracellular PKM2 at wound site can 
stimulate fibroblasts and myofibroblast differentiation through integrin αvβ3.  
In our preliminary study of liver fibrosis, we found that the level of extracellular PKM2 is 
gradually increased in the liver fibrosis and cirrhosis patients. The expression level of integrin 
αvβ3 is correlated with the level of extracellular PKM2. The activated HSCs express high level 
of integrin αvβ3 during liver fibrosis. Given that the activation of integrin αvβ3 mediate the 
survival pathway, we hypothesizes that extracellular PKM2 released by neutrophils prevents 
HSCs from apoptosis, thus worse liver fibrosis. 
In this dissertation, the aim is divided into three parts. First, I examine the effect of 
extracellular PKM2 during wound healing process. Second, I study the interaction between 
PKM2 and fibroblasts in the case of myofibroblast differentiation. Last, I test the function of 
extracellular PKM2 against HSCs in liver fibrosis. Here, I demonstrated that topical application 
of PKM2 promoted wound healing process through activating angiogenesis. The extracellular 
PKM2 at wound site was released from neutrophils under the influence of degranulation. On the 
other hand, neutralization of extracellular PKM2 during wound healing inhibited the process. I 
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claimed that PKM2 activated myofibroblast differentiation through "αvβ3-PI3K-PAK2" 
pathway, which was independent of the classical "TGFβ-Smad" pathway. I also demonstrated 
that extracellular PKM2 protected HSCs from apoptosis via integrin αvβ3 survival pathway 
during liver fibrosis. Neutralization of extracellular PKM2 during liver fibrosis relieved the 
stress of liver fibrosis. Therefore, I established a connection between inflammatory response and 
differentiation in physiopathological condition that extracellular PKM2 released from 
neutrophils activates endothelial cells and fibroblasts in both wound healing and liver fibrosis. 
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Figure 1.1 Locations and functions of PKM2 
    
PKM2 converts PEP to pyruvate in cytosol. PKM2 can translocate in to cell nucleus and 
extracellular space. Nuclear PKM2 acts as protein kinase to phosphorylate histone H3 and 
STAT3. PKM2 also interacts with transcription factors to induce cell proliferation. Extracellular 
PKM2 is used as serum marker for multiple cancers and immune diseases. Cancer cells secrete 
PKM2 to promote angiogenesis by activating endothelial cell proliferation and migration. 
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Figure 1.2 Wound healing process 
 
Wound healing process is divided into four stages, hemostasis, inflammation, proliferation and 
maturation. Each stage is well regulated by different factors in order. The whole wound healing 
process takes months to years to heal. 
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Figure 1.3 Liver fibrogenesis 
 
After activation by different stimulators, quiescent HSCs transform into activated HSCs and 
secret large amount of extracellular matrix. If this is unsolved and lasts for several years, healthy 
liver is damaged and becomes fibrotic. Advanced liver fibrosis develops into cirrhosis, and has 
higher incidence of hepatocellular carcinoma. 
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CHAPTER 2 EXTRACELLULAR PYRUVATE KINASE M2 RELEASED FROM 
NEUTROPHILS FACILITATES EARLY WOUND HEALING BY PROMOTING 
ANGIOGENESIS
1 
1
 This chapter was published in Wound Repair and Regeneration. 
2.1 Abstract 
During wound healing, neutrophil infiltration represents the early inflammation response 
to function in cleaning microbes. However, the role of activated neutrophil in tissue regeneration 
is still not well understood. Here, we report that the activated neutrophils at wound site release 
PKM2 through degranulation at the early stage of wound healing. Extracellular PKM2 facilitates 
wound healing by promoting angiogenesis. Our study reveals a new molecular connection 
between early inflammation response and proliferation phase in wound repair.  
2.2 Introduction 
Cutaneous wound healing is a complex process that skin tissue repairs itself after injury. 
After wound induction, hemostasis first occurs and broken blood vessels are clotted by platelets. 
Different types of immune cells infiltrate into wound site to clean microorganisms and stimulate 
the later proliferation stage. Macrophage is considered the major source of activating 
angiogenesis, whereas neutrophil mainly plays a role in cleaning microbes and dead cell debris. 
However, several studies have showed that the function of infiltrated neutrophil is still 
controversial, that neutrophil is found to inhibit re-epithelialization, but also promote 
angiogenesis during wound healing (Singer & Clark, 1999). 
Pyruvate kinase is an enzyme acts at the last step of glycolysis that converts PEP to 
pyruvate to generate ATP. There are four isoforms of pyruvate kinases, L/R and M1/M2. PKM1 
and PKM2 are transcribed from the same mRNA with alternative splicing. PKM2 is expressed in 
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highly proliferating cells with low pyruvate kinase activity compared with other pyruvate 
kinases. The inactivation of PKM2 slows the process of glycolysis, that more biosynthesis 
building blocks are accumulated in favor of cell proliferation. In addition to the role in 
glycolysis, PKM2 is involved in other biological processes, such as transcription regulation, 
immune response, and metabolism control (Mazurek et al., 2005). 
High level of PKM2 is found in the blood stream of cancer patients. Serum and stool 
PKM2 levels have been used as diagnostic marker for various cancers. The level of PKM2 in 
blood circulation is strongly correlated with progression of cancer (Mazurek, 2007). Our 
laboratory previously discovered that extracellular PKM2 promoted tumor growth by activating 
angiogenesis. Extracellular PKM2 interacted with integrin αvβ3 on cell surface and stimulated 
proliferation and migration of endothelial cells. PKM2 is also detected in the blood stream of 
various inflammation diseases. Given that PKM2 is expressed in the immune cells, the function 
of extracellular PKM2 might be correlated with inflammation. 
2.3 Results 
2.3.1 rPKM2 facilitates wound healing by activating angiogenesis. 
We previously found that recombinant PKM2 (rPKM2) plays an important role in tumor 
angiogenesis. Since angiogenesis is a key stage during wound healing, we first tested the topical 
application of rPKM2 mixing with cream in the wound healing CD-1 mouse model. Buffer and 
rPKM1 were used as controls. After wound induction, the size of wound was measured on day 0, 
day 3, day 6, and day 8 (Figure 2.1 A). The quantitative curve showed that rPKM2 group had 
smaller wound area on day 3 and day 6 compared with rPKM1 and buffer groups. The 
differences among three groups were not significant on day 8 (Figure 2.1 B). From skin wound 
pictures, the wound size was smaller in rPKM2 group, compared with rPKM1 and buffer groups 
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on day 3. The difference was more significant on day 6. The wound size in all groups on day 8 
looked similar (Figure 2.1 C). In a word, topical application of rPKM2 facilitates wound healing 
process.  
To test the angiogenic effect during wound healing, skin tissue at wound site was stained 
with CD-31 (endothelial cell marker) using immunofluorescence staining. rPKM2 group showed 
more condensed signal compared with the staining in rPKM1 and buffer groups (Figure 2.2 A). 
To quantify the immunofluorescence staining, we analyzed the micro vesicular density (MVD) 
and the area covered by CD31 positive staining. rPKM2 group showed significant increase in 
both MVD and CD31 positive area (Figure 2.2 B&C). As a result, topical application of rPKM2 
promotes wound healing by activating angiogenesis. 
2.3.2 rPKM2 promotes granulation tissue growth during wound healing 
Angiogenesis and the growth of granulation tissue are strongly connected with the 
proliferation stage of wound healing. Since topical application of rPKM2 promotes angiogenesis, 
we pursued the effect of rPKM2 on the growth of granulation tissue. Granulation tissue is formed 
during the proliferation stage of wound healing. It consists of connective tissue and capillary 
networks that build up from the bottom of the wound and fill the whole wounded area. It also 
protects the wound from further infection. After proliferation stage, granulation tissue gradually 
remodels to normal skin or tissue. It is important to have the proper granulation tissue growth 
during wound healing. The growth of granulation tissue at early time of wound healing indicates 
a start of the proliferation stage. By measuring the thickness of granulation tissue (distance from 
bottom to top of the granulation tissue), we can analyze the process of wound healing, and how 
the wound is healed. 
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We first examined the inner side of wound skin. rPKM2 group had complex capillary 
structure and thick granulation tissue, whereas rPKM1 and buffer groups had thin granulation 
tissue, or even transparent membrane structure (Figure 2.3 A). To quantify the thickness of 
granulation tissue, the slides with vertical cut were stained by H&E staining. The thickness of 
granulation tissue was measured from the outside to the inside of wound skin. As a result, the 
thickness of granulation started to increase as early as day 3 in rPKM2 group. This effect 
continuously maintained till the end of the experiment (Figure 2.3 B). To further analyze the 
growth of granulation tissue, fibroblast was stained in the frozen section of wound skin using 
fibroblast marker (ER-TR7). rPKM2 group had more condensed fibroblast signal compared with 
rPKM1 and buffer groups. The quantified result showed that the fibroblast positive area was 
doubled in rPKM2 group (Figure 2.3 C). In summary, Topical application of rPKM2 stimulates 
the growth of granulation tissue during wound healing. 
2.3.3 Application of PKM2 antibody slows wound healing process 
Given the effect of rPKM2 during mouse cutaneous wound healing, we generated a new 
mouse wound healing model using PKM2 antibody to neutralize extracellular PKM2 during 
wound healing. Buffer and IgGCon were used as controls. The rabbit monoclonal PKM2 
antibody was first I.P. injected into CD-1 mice one day before wound induction to let it circulate 
in the blood system. The following procedure was similar as in the previous wound healing 
experiment (Figure 2.4 A&B). The healing speed of wound was slower in IgGPK group 
compared with buffer and IgGCon groups (Figure 2.4 C). From the quantitative curve, IgGCon 
and buffer groups were at the same trend, compared with IgGPK group with a slow start from 
day 2. This inhibition effect continued till day 8 (Figure 2.4 B). 
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To determine the effect of PKM2 antibody in angiogenesis, we performed the same 
CD31 staining and quantified with MVD and CD31 positive area. We clearly saw the capillary 
structure in buffer and IgG groups, even tube structure in buffer group. The density and length of 
vessels were significantly decreased in IgGPK group. The quantified data showed that both 
MVD and CD31 positive area were reduced under the treatment of PKM2 antibody (Figure 2.5 
B&C). 
2.3.4 PKM2 was released from neutrophils in wound healing 
To find out whether PKM2 is endogenous in wound healing, we collected the skin 
samples on day 3 of wound healing in both rPKM2 treated and non-rPKM2 treated groups. 
Samples were paraffin embedded and stained with PKM2 antibody for IHC. The non-wound 
tissue did not have any positive signal of PKM2. In wound tissue, compared with rPKM2 treated 
sample, non-rPKM2 treated one had light signal of PKM2 positive staining (Figure 2.6 A). This 
indicated that PKM2 was endogenous during wound healing. In cancer progression, PKM2 is 
secreted by cancer cells and locates in the extracellular space. After observation under higher 
magnification, we found that most PKM2 located in the extracellular space (Figure 2.6 B). The 
cells containing intracellular PKM2 had similar polymorphonuclear phenomenon like 
neutrophils. We suspected that neutrophils are the resource of extracellular PKM2 during wound 
healing. To test the correlation between extracellular PKM2 and neutrophils, we generated a 
time-series wound skin samples from day 0 to day 5 and stained the samples with PKM2 and 
Ly6G antibody (neutrophil marker). By quantifying the positive signal in each staining, we 
observed a similar pattern of increase and decrease in PKM2 and Ly6G staining (Figure 2.6 
C&D). This meant that the presence of neutrophils is highly correlated with extracellular PKM2.  
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We used in vitro system to study the release of PKM2 from neutrophils. Neutrophils were 
isolated from mouse bone marrow and activated with fMLP and damnacanthal for 15 min. Both 
culture medium and cell lysates were collected for immunoblot. The medium PKM2 level was 
increased in the fMLP and damnacanthal treatments (Figure 2.7 A&B). We also obtained a 
sucrose gradient sample of neutrophil fractionation from Dr. Yuan Liu's lab. Two sets of 
samples, inactivated neutrophils and fMLP activated neutrophils were examined by immunoblot 
using PKM2, β-actin (represents cytosolic part) and CD11b (represents granule part) antibodies. 
In the inactivated neutrophils, PKM2 located in the cytosol as β-actin. In the fMLP activated 
neutrophils, PKM2 had another fraction in granules as CD11b. In summary, we revealed that 
PKM2 is released from activated neutrophils. 
2.3.5 Inhibition of neutrophil infiltration reduces extracellular PKM2 
To further test the correlation between extracellular PKM2 and neutrophils, we used 
beige-J mouse, a mouse strain with neutrophil infiltration defect, as the model in wound healing 
study. At day 3 after wound induction, wild-type group had reduced wound size compared with 
beige group (Figure 2.8 A). On the other hand, wild-type group had thicker granulation tissue 
(Figure 2.8 B). IHC staining of wound sites showed that wild-type group had both Ly6G and 
PKM2 positive signals, but beige group had no signal (Figure 2.8 C). This indicated that beige-J 
mice had reduced extracellular PKM2 at wound site as a result of defective neutrophil 
infiltration. To further confirm the correlation between extracellular PKM2 and neutrophils, we 
also applied rPKM2 to the wound of beige-J mouse to test whether this application can overcome 
the defect. Reasonably, rPKM2 application increased the speed of wound healing, but it was still 
slower compared with wild-type mouse (Figure 2.8 D). 
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2.3.6 Identification of PKM2 release from neutrophil degranulation 
To test whether degranulation is the way to release PKM2, we used several degranulation 
inhibitors. PP1, SB 203580, and piceatannol were pre-treated before fMLP activation. Compared 
with fMLP activation of PKM2 level in the culture medium, the inhibitors treated ones had 
different degrees of reduction. Piceatannol had the best inhibitory effect among three inhibitors 
(Figure 2.9 A). We also examined the time-series of fMLP activation in PKM2 release. We 
picked up 5 min, 10 min, and 30 min to test the level of released PKM2 in the culture medium, 
which showed gradually increasing (Figure 2.9 B&C). In summary, in vitro cell analysis 
demonstrated that PKM2 is released by neutrophils through degranulation. 
2.4 Discussion 
Wound healing is a slow and complex process. Opened wound area causes several 
infection problems. To prevent infection and seal wound at an early time is the major goal of fast 
wound healing. Different immune cells function in cleaning microorganisms and promoting 
granulation tissue formation. A major question in wound healing process is what is role of 
immune cells during the early stage of wound healing. Here we found that neutrophils as the 
early resources of immune cells release PKM2 to facilitate granulation stage of wound healing. It 
fills a gap between early inflammation and proliferation stage. We demonstrated that PKM2 is 
released from neutrophils via degranulation process. The extracellular PKM2 activates 
angiogenesis and promotes the growth of granulation tissue in proliferation stage. We followed 
up to use PKM2 antibody to inhibit the connection between neutrophil infiltration and 
granulation tissue growth. The wound healing was significantly slowed and the angiogenic effect 
was reduced.  
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Another question is why and how neutrophils release PKM2. Neutrophil is one of the 
earliest immune cells arrive at wound site. Neutrophil infiltration reaches to a peak around 48 to 
72 hours in mouse cutaneous wound. High density of neutrophils accumulates at wound site and 
release large amount of PKM2 to stimulate angiogenic activity. The induced angiogenesis 
supports the later coming fibroblasts to build up granulation tissue. Extracellular PKM2 plays an 
important role in early wound healing process as the connection between inflammation and 
proliferation stage. Neutrophils have several secretory pathways for protein transportation. Since 
PKM2 is a cytosolic protein, the classic secretory pathway which needs membrane recognition 
peptide is not the proper transporting method. Our experiments showed that the release of PKM2 
was highly correlated with degranulation. PKM2 level was gradually increased in the culture 
medium of activated neutrophils and was significantly reduced under the effect of degranulation 
inhibitors. We thought PKM2 in cytosol was interacted with the protein in or on the granules and 
was coupled transported out of the cells during degranulation. 
2.5 Materials and Methods 
2.5.1 Mouse Wound Healing Model 
All animal experiments were carried out in accordance with the guidelines of IACUC of 
Georgia State University. CD-1 mice were anesthetized with 3% isoflurane and kept under 
anesthesia during the whole surgery process. The furs on back of mice were shaved with 
electronic hair shaver and further cleared with Nair (Church & Dwight Co Inc.). The shaved 
areas were cleaned and aseptically prepared with cotton swabs soaking in antiseptic surgical 
scrub solution and 70% alcohol alternatively for three times. The body temperature of mouse 
was maintained by using a circulating water bed. The surgical areas were kept sterile throughout 
the surgery process. The wounds were induced by using a 6 mm diameter dermatology biopsy 
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punch. The photo of wound was taken and the size was measured by caliper. Vanicream (Stacy's 
Compounding Pharmacy) mixed with buffer, rPKM1 or rPKM2 was applied on the wound. The 
wounds were then dressed with transparent adhesive films, and wrapped with adhesive tapes. 
The mice were carefully monitored during surgery and 30 min after, and then single housed to 
prevent scratching. The wounds were re-opened and same procedure of cream application and 
dressing were performed on day 3, day 6. The mice were euthanized on day 8 by CO2. Skin 
wound samples were collected and put in frozen section or paraffin embedded. The slides were 
cut vertically across the wound area. 
2.5.2 Tissue Sample Preparation 
The wounded areas were cut off for sample preparation. For the frozen tissue, the 
samples were immersed in the OCT solution and snap-frozen in liquid nitrogen. The frozen 
section slides were cut with cryostat. For paraffin embedding tissue, the samples were incubated 
in the formalin solution at room temperature for two days, and then stored at 4 ˚C in 70% 
ethanol. The paraffin embedding process was done by using Citadel with the standard protocol, 
and then embedded with Histostar. The paraffin embedding section slides were cut with 
microtome. 
2.5.3 H&E Staining 
The paraffin slides were baked at 60 ˚C for 2 hours, and then incubated with the 
following solutions 5 min each in order (three times xylene, twice 100% ethanol, 90% ethanol, 
70% ethanol, 50% ethanol, 30% ethanol, and distilled water). The slides were incubated with 
0.1% Mayers Hematoxylin for 5 min and washed with running water. The slides were dipped in 
0.5% Eosin for 1 min and then washed with water. The slides were dehydrated by incubated with 
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the previous solutions reversely. At last, the slides were mounted with mounting medium and 
covered by coverslip. The coverslips were sealed with nail polish and waited for one day to dry. 
2.5.4 Measurement of Granulation Thickness 
The pictures shown in the figure were taken by camera. The wound skin samples were 
cut off and flipped over. The H&E staining slides from buffer and rPKM2 group at different time 
points were observed under microscope. The distance between out-layer and inner-layer of skin 
was measured for each slide. All results were averaged and normalized with the result of buffer 
group on day 3.  
2.5.5 Neutrophil Isolation 
CD-1 mice were killed, and the femur and tibia were removed and cleaned. HBSS-EDTA 
was injected through the bone to push out cell clumps. The cells were washed once with HBSS, 
laid on a three-layer Percoll gradient (78%, 69%, and 52% from bottom to top), and then 
centrifuged at 1500 g for 30 min. The upper part of 78% and interface between 78% and 69% 
were collected and washed twice with HBSS-EDTA. The cells were resuspended in HBSS-
EDTA for later experiment. 
2.5.6 Activation of Neutrophils 
To evaluate the release of PKM2 to culture medium, isolated neutrophils were treated 
with 1 μM fMLP at 37 ˚C for 20 min or 1 μM damnacanthal at 25 ˚C for 20 min in HBSS, and 
then centrifuged to collect the medium for following ELISA and Western blot. Cell pellets were 
lysed with RIPA buffer for the analysis of cytosol components. For the inhibitor assay, cells 
were pretreated with PP1 (10 μM), SB 203580 (1 μM), and piceatannol (20 μM) for 15 min, 
followed by same fMLP stimulating procedure. For the time series assay, cells were treated with 
1 μM fMLP at 37 ˚C for 5, 10, and 30 min, respectively. 
37 
2.5.7 Beige Mice Wound Healing Protocol 
The beige mutant and wildtype mice were purchased from The Jackson Laboratory. The 
wound was generated same as in the CD-1 mice previously. Generally, mice were anesthetized 
and kept under anesthesia during the whole surgical procedure. The furs on back of mice were 
shaved and the surgical site on mouse back was cleaned and aseptically prepared. The wounds 
were induced by using a 6 mm diameter dermatology biopsy punch, and then dressed with 
transparent adhesive film (3M), and wrapped with adhesive tape. The mice were euthanized on 
day 3, and the wounded skins were cut off and processed for paraffin embedding. 
2.5.8 Sucrose Gradient Centrifugation 
Freshly isolated neutrophils were lysed and loaded onto a prepared sucrose gradient from 
50% at bottom to 20% at top. After centrifugation at 66000 x g for 90 min, fractions were 
collected and prepared for immunoblot. 
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Figure 2.1 Topical application of rPKM2 facilitates wound healing. 
(A). Diagram of mouse wound healing experiment. Cutaneous wounds were induced on the back 
of three groups of mice on day 0, and applied with cream mixing buffer, rPKM1, and rPKM2 
respectively. The cream mixing with reagent was re-applied on day 3 and day 6. All mice were 
euthanized on day 8. (B). Quantitative analysis of wound size. Wound size was measured on day 
0, day 3, day 6, and day 8. The size of day 0 was set as 100%, and gradually reduced by healing. 
(C). Pictures of wound. Pictures were taken by camera on day 0, day 3, day 6, and day 8.  
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Figure 2.1 Topical application of rPKM2 facilitates wound healing. 
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Figure 2.2 Topical application of rPKM2 activates angiogenesis during wound healing. 
(A). Immunofluorescence staining of CD31. Wound skin samples were cut off and snap-froze in 
opti medium in liquid nitrogen. Frozen sections were cut vertically through the wound area. 
CD31 was stained in green and DAPI was in blue. (B). Quantification of CD31 staining. 
Quantification was processed by ImageJ. Microvescular density was quantified by counting each 
staining pattern. CD31 positive pixel was quantified by calculating the area of CD31 staining. 
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Figure 2.2 Topical application of rPKM2 activates angiogenesis during wound healing. 
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Figure 2.3 Topical application of rPKM2 induces granulation tissue growth during wound 
healing. 
(A). Pictures of inner side of wounded skin. The wounded skin was cut off at day 8. The pictures 
were taken after flipping and spreading the wounded skin. (B). Quantification of thickness of 
granulation tissue. The wounded skin was cut off at day 3, day 6, and day 8, and embedded in 
paraffin for vertical sliding. The slides were performed with H&E staining. The thickness was 
measured by the length from the outside to the inside of wounded skin on H&E stained slide. 
The measurements were averaged and compared between buffer and rPKM2 groups. (C). 
Immunofluorescence staining of fibroblast and quantification. The fibroblast was stained in 
green with fibroblast marker ER-TR7, and DAPI was in blue. Quantification was processed by 
ImageJ. ER-TR7 positive pixel was quantified by calculating the area of staining. 
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Figure 2.3 Topical application of rPKM2 induces granulation tissue growth during 
wound healing. 
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Figure 2.4 Neutralization of extracellular PKM2 inhibits wound healing process. 
(A). Diagram of mouse wound healing experiment. Cutaneous wounds were induced on the back 
of three groups of mice on day 0, and applied with cream mixing buffer, IgGCon, and IgGPK 
respectively. The cream was re-applied on day 2 and day 4. All mice were euthanized on day 8. 
(B). SDS-PAGE of antibody pair, IgGCon vs IgGPK. Immunoblot of IgGPK on whole cell 
lysate of SW480 cell. (C). Quantitative analysis of wound size. Wound size was measured on 
day 0, day 2, day 4, day 6, and day 8. The size of day 0 was set as 100%, and gradually reduced 
by healing. (D). Pictures of wound. Pictures were taken by camera on day 0, day 2, day 4, day 6, 
and day 8.  
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Figure 2.4 Neutralization of extracellular PKM2 inhibits wound healing process. 
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Figure 2.5 Neutralization of extracellular PKM2 reduces angiogenesis. 
(A). Immunofluorescence staining of CD31. Wound skin samples were cut off and snap-froze in 
opti medium in liquid nitrogen. Slides were cut vertically through the wound area. CD31 was 
stained in green and DAPI was in blue. (B). Quantification of CD31 staining. Quantification was 
processed by ImageJ. Microvescular density was quantified by counting each staining pattern. 
CD31 positive pixel was quantified by calculating the area of CD31 staining. 
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Figure 2.5 Neutralization of extracellular PKM2 reduces angiogenesis. 
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Figure 2.6 Identification of extracellular PKM2 in wound healing. 
(A). Immunohistochemistry staining of PKM2 in wounded skin samples. Wounded skin at day 2 
were cut and embedded in paraffin. Samples were cut vertically and stained with PKM2 antibody. 
The results were compared between non-wound tissue, wound tissue and wound tissue treated 
with rPKM2. (B). Identification of extracellular PKM2 in 10X and 40X magnification. (C). Time 
series of PKM2 and Ly6G staining. Mouse wounded skin samples from day 0 to day 5 were cut 
and embedded in paraffin. Samples were cut vertically and stained with PKM2 or Ly6G 
respectively. (D). Quantification of time series of PKM2 and Ly6G staining. Quantification was 
processed by FRamework for Image Dataset Analysis (FRIDA). 
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Figure 2.6 Identification of extracellular PKM2 in wound healing. 
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Figure 2.7 In vitro analysis of extracellular PKM2 released by neutrophils. 
(A). Release of PKM2 by neutrophils under degranulation stimulation. Neutrophils were isolated 
from mouse bone marrow and activated with fMLP and damnacanthal. Whole cell lysate and 
concentrated culture media were analyzed by Western blot using PKM2 and β-actin antibody. 
(B). Quantification of released PKM2 by ELISA. Isolation and activation of neutrophils were 
performed the same as in Western blot. Culture media were added into ELISA plate coated with 
PKM2 antibody. Level of released PKM2 was measured with another PKM2 antibody and then 
recorded by spectrophotometer. (C). Presence of PKM2 in sucrose gradient fractions of activated 
neutrophils. Sucrose gradient fractions of neutrophils were analyzed with PKM2, β-actin, and 
CD11b antibodies using Western blot. 
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Figure 2.7 In vitro analysis of extracellular PKM2 released by neutrophils. 
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Figure 2.8 Identification of extracellular PKM2 in wounded beige-J mouse. 
(A).Wound size comparison between beige and WT mice at day 3.  Wound was induced the 
same as in CD-1 mice. (B). Granulation in beige and WT mice at day 3. Wounded skin was cut 
off and processed with H&E staining to measure the thickness of granulation. (C). 
Representative images of IHC staining of wound tissue sections from beige-J and WT mice. 
Wound skin tissue was collected at day 3. 
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Figure 2.8 Identification of extracellular PKM2 in wounded beige-J mouse. 
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Figure 2.9 Inhibition and time series of extracellular PKM2 released from neutrophils.  
(A). Inhibition of PKM2 release by degranulation inhibitors. Neutrophils were isolated and 
activated by fMLP. PP1, SB 203580, and piceatannol were tested under fMLP stimulation. 
Whole cell lysate and culture media were analyzed using Western blot. (B). Time series of 
PKM2 release in neutrophils. Neutrophils were activated by fMLP and culture media were 
collected at different time points for Western blot analysis. (C). Quantification of time series 
released PKM2 by ELISA. Culture media were added into ELISA plate coated with PKM2 
antibody. The level of released PKM2 was measured with another PKM2 antibody and then 
recorded by spectrophotometer. 
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Figure 2.9 Inhibition and time series of extracellular PKM2 released from neutrophils. 
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CHAPTER 3 EXTRACELLULAR PYRUVATE KINASE M2 ACTIVATES DERMAL 
MYOFIBROBLAST DIFFERENTIATION
 
3.1 Abstract 
Extracellular PKM2 released from neutrophils promotes wound healing by activating 
angiogenesis. In addition, we claim that extracellular PKM2 can also activate dermal fibroblasts 
to undergo myofibroblast differentiation. PKM2 facilitates the formation of early granulates at 
wound site by promoting fibroblast migration and myofibroblast differentiation. We demonstrate 
that extracellular PKM2 promotes myofibroblast differentiation through a TGFβ independent 
pathway via activation of integrin αvβ3 signaling. Our studies discover another function of 
extracellular PKM2 during wound healing to link early inflammation response with proliferation 
stage. Our studies also uncover a novel mechanism of stimulating myofibroblast differentiation. 
3.2 Introduction 
Myofibroblast differentiation is a key process during the proliferation stage of wound 
healing. Fibroblasts are recruited to the wound site by growth factors and cytokines released 
from immune cells. Together with endothelial cells, fibroblasts build up the granulation tissue to 
fill up wound area. After wound closure, fibroblasts convert to myofibroblasts to further contract 
the wound and secret extracellular matrix to support wound repair (Hinz, 2007). 
TGFβ is the major ligand to activate myofibroblast differentiation. TGFβ activates TGFβ 
receptor on the plasma membrane fibroblasts. The activated TGFβ receptor heterodimer 
phosphorylates Smad complex to induce the nuclear translocation of Smad complex that leads to 
the upregulation of several fibroblast differentiated gene transcription, including α-SMA.  
Integrin αvβ3 also involved in myofibroblast differentiation (Gressner et al., 2002). Previously 
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we found that extracellular PKM2 promotes endothelial cells migration and attachment through 
integrin αvβ3.  
3.3 Results 
3.3.1 Myofibroblast differentiation is activated in rPKM2 treated wound 
After examining the inside of wounded skin, we found that granulation tissue was grown 
much thicker in rPKM2 group. We questioned whether other effects of extracellular PKM2 
existed besides activation of endothelial cells. Given that both endothelial cells and fibroblasts 
have integrin αvβ3 expression, we hypothesized that extracellular PKM2 also activated dermal 
fibroblasts during wound healing. We first checked myofibroblast differentiation in the wound 
skin sample. Frozen sections were stained with α-SMA antibody via immunofluorescence 
staining. The rPKM2 treated mice had increased level of α-SMA at wound site (Figure 3.1 
A&B). Three time points as in granulation tissue thickness measurement were picked up for 
staining of α-SMA expression. On day 3, day6, and day 8, the rPKM2 treated mice all showed 
elevated levels of α-SMA (Figure 3.1 C). The PKM2 antibody treated group was also tested and 
the α-SMA level was reduced (Figure 3.1 D). Since other type of cells in skin also had αvβ3 
expression, such as smooth muscle cells. To exclude the possibility of smooth muscle cells and 
also confirm the fibroblast staining, frozen sections were co-stained by α-SMA and smooth 
muscle cell marker myosin or fibroblast marker ER-TR7. Myosin and α-SMA had different 
staining pattern, on the other hand, ER-TR7 staining was overlapped with α-SMA expression 
pattern (Figure 3.2 A). In summary, myofibroblast differentiation is activated in the PKM2 
treated mice during wound healing. 
58 
3.3.2 Effect of extracellular PKM2 on HDFa  
To test the effect of PKM2 on fibroblasts, human dermal fibroblasts adult (HDFa) were 
treated with rPKM2 and tested in proliferation and migration assays. In BrdU proliferation assay, 
rPKM2 treated HDFa had a little bit increase compared with the controls, but it was not 
significant (Figure 3.2 B). In boydem chamber assay, rPKM2 treated cells had three-fold 
increase compared with the controls (Figure 3.2 C). After 48 hours of rPKM2 treatment, HDFa 
cells had increased expression of α-SMA in the immunoblot test. It was slightly less compared 
with the TGFβ treatment. Combination of rPKM2 and TGFβ treatment had enhanced α-SMA 
expression (Figure 3.3 A). To detect the differentiating features, HDFa were treated with rPKM2 
or TGFβ, and then stained with phalloidin, α-SMA, and DAPI. HDFa cells in buffer group still 
remained the spindle shape, and the expression level of α-SMA was low. Both rPKM2 and TGFβ 
treated cells had the typical myofibroblast spreading shape and the signal α-SMA expression was 
stronger. Actin (Red) and α-SMA (green) formed bundles in yellow. In rPKM2 group, HDFa 
cells had more protrusions structures (Figure 3.3 B). Collagen level in culture medium was also 
increased in rPKM2 and TGFβ treated cells (Figure 3.3 C). 
3.3.3 Extracellular PKM2 activates HDFa cells through integrin αvβ3 
In the previous study, we found that extracellular PKM2 activates endothelial cells 
through integrin αvβ3 signaling. Since HDFa also have integrin αvβ3 on the cell surface, we 
questioned whether it was the same cell surface receptor on HDFa for extracellular PKM2. First, 
in vitro cell attachment assay was used to test the interaction between integrin αvβ3 and PKM2. 
HDFa only attached on rPKM2 coated plate and this effect was eliminated by the pretreatment of 
αvβ3 antibody (Figure 3.4 A). We carried out chemical crosslinking with rPKM2 and the 
membrane extracts of HDFa using glutaraldehyde as a crosslinker. The crosslinked proteins were 
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separated by His-tag pull-down and subsequently digested by trypsin. The digested integrin αvβ3 
peptides were found in the mass spectrometry result (Figure 3.4 C). To further confirm the 
interaction between PKM2 and integrin αvβ3, we also tested the pull-down assay by PKM2 
antibody and control antibody in western blot. Integrin β3 was detected in PKM2 antibody 
group, but not in control antibody group (Figure 3.4 B). Furthermore, in the migration activity 
assay, the αvβ3 antibody reduced the level of migration down to the buffer level (Figure 3.4 D). 
TGFβ pathway is the well-known pathway to activate myofibroblast differentiation. We 
then asked whether PKM2-αvβ3 signaling was independent of TGFβ signaling pathway. Two 
additional treatments were used. TGFβ antibody was pretreated to neutralize the possible TGFβ 
residue in culture medium, and TGFβ receptor inhibitor was used to block TGFβ signaling 
pathway. Both of them were added into rPKM2 and TGFβ treatments respectively. As shown in 
the immunoblot, rPKM2 or TGFβ treatments induced the expression of α-SMA. Phospho-
Smad2, the downstream signal of TGFβ signaling, was activated in TGFβ treatment, but not in 
rPKM2 treatment. Upon addition of TGFβ antibody or TGFβ receptor inhibitor, both α-SMA and 
p-Smad2 signal were lost in TGFβ treated cells. However, rPKM2 treatment was still able to 
induce α-SMA expression (Figure 3.5 A). Since PKM2 interacts with integrin αvβ3 on the cell 
surface of HDFa, we pretreated integrin αvβ3 antibody and the expression of α-SMA was 
reduced (Figure 3.5 B). FAK activation is the major downstream target of integrin αvβ3. If 
extracellular PKM2 activates HDFa through integrin αvβ3, then FAK should be activated. 
Phospho-FAK was detected as the signal of FAK activation. The rPKM2 treatment stimulated 
both expression α-SMA and phosphorylation of FAK, which were abolished after the treatment 
of FAK inhibitor (Figure 3.5 C). 
60 
Then we questioned what the downstream signal pathway of PKM2-αvβ3-FAK was. We 
first screened with several FAK downstream pathway inhibitors. PI3K, Src, and MEK inhibitors 
were applied and PI3K inhibitor showed the strongest inhibition in α-SMA expression (Figure 
3.6 A). To further confirm this effect, we tested PI3K activity with treatment of rPKM2. Buffer 
treatment was normalized to baseline, and rPKM2 treatment had three-fold increase with or 
without addition of TGFβ receptor inhibitor. In addition, pretreatment of FAK inhibitor brought 
PI3K activity down to the baseline level (Figure 3.6 B). It is reported that PAK2 is activated by 
PI3K and plays a role in myofibroblast differentiation. We followed this track to test activation 
of PAK2 with the treatment of rPKM2. The rPKM2 treated HDFa cells stimulated the 
phosphorylation of PAK2 compared with rPKM1 and buffer controls (Figure 3.6 C). 
3.4 Discussion 
Myofibroblast differentiation is a critical pathophysiology process involved in different 
circumstances, including wound healing and fibrosis. We first noticed the granulation tissue was 
very thick in the previous wound healing experiment. Only by angiogenesis is not enough to 
grow such level of granulation tissue. Given the similar features between endothelial cells and 
fibroblasts, we tested the effect of extracellular PKM2 on dermal fibroblasts. Extracellular 
PKM2 activated the differentiation of myofibroblast through integrin αvβ3 and PI3K signaling 
pathway during wound healing.  
One question is why extracellular PKM2 is the stimulator in addition to TGFβ. TGFβ is 
the well-known major growth factor to activate myofibroblast differentiation via Smad family 
signaling pathway. We found that rPKM2 activated dermal fibroblasts independent of TGFβ 
through integrin αvβ3. It is reported that only TGFβ is not enough to transit quiescent fibroblast 
to myofibroblast and TGFβ activation can change the transcription profile of fibroblast, such as 
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increase of integrin αvβ3 expression level. Thus, during wound healing, fibroblasts are attracted 
to wound area and activated by TGFβ first. After the increase of integrin αvβ3 level, 
extracellular PKM2 further converts myofibroblast differentiation. That was why the 
combination of rPKM2 and TGFβ had the strongest effect in α-SMA stimulation. 
3.5 Materials and Methods 
3.5.1 Induction of HDFa Differentiation 
HDFa were cultured to reach 70% confluency, and starved with serum-free medium 
overnight before differentiation induction. The cells were treated with TGF-β (10 ng/mL) or 
rPKM2 (0.1 µM) for 2 days. After treatment, the cells were lysed with RIPA buffer and medium 
was collected for further analysis. Cell lysates prepared with RIPA buffer and culture media 
were collected and analyzed with western blot. 
3.5.2 Cells Immunofluorescence Staining 
HDFa seeded on the coverslips were fixed with 4% paraformaldehyde for 15 min and 
then permeabilized with 0.1% Triton X-100 in PBS for 15 min. HDFa were washed twice with 
PBS and blocked with 5% BSA solution at room temperature in humidity box for 30 min. HDFa 
were incubated with primary α-SMA antibody with 1:500 dilutions in 5% BSA solution at 4 ˚C 
overnight. HDFa were washed with PBST three times each time 5 min and then incubated with 
secondary antibody conjugated with fluorescence dye at room temperature for 30 min. If another 
fluorescence dye was needed, the slides were incubated with another primary antibody at room 
temperature for 2 hours and secondary antibody conjugated with fluorescence dye for 30 min. 
The slides were washed and mounted with Prolong Gold Antifade Mountant with DAPI. The 
coverslips were sealed by nail polish. The results of immunofluorescence staining were acquired 
by using Zeiss LSM 700 Confocal. 
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3.5.3 Cell Attachment Assay 
HDFa were cultured in good condition. rPKM1, rPKM2 or BSA was coated on the 24-
well plate at 4 ˚C overnight. The wells were washed with PBS twice and then blocked with 5% 
BSA at room temperature for 1 hour. HDFa were trypsinized and pre-treated with LM609 or 
BSA as control. HDFa were seeded on the plate and incubated for 2 to 4 hours. After wash twice 
with PBS, the unattached cells were washed and the attached cells were stained with crystal 
violet. The cell number in each well was counted for comparison of the cell attachment. 
3.5.4 Crosslink 
HDFa were harvested and washed with PBS. The membrane proteins were extracted by 
using a membrane protein extraction kit. The membrane protein lysates were incubated with 
rPKM2 at room temperature for 2 hours. Glutaraldehyde (1:100) was added in the reaction and 
incubated for another 30 min. 1 M Tris/glycine was added into to the reaction to reach a final 
concentration of 100 mM to stop the crosslink reaction. The magnetic Ni
2+
 beads were added in 
to the lysate and incubated at room temperature for 1 hour. The beads were washed 3 times with 
PBS, and then eluted by imidazole. The elution was dialyzed in ammonium bicarbonate at 4 ˚C 
twice each time 4 hours. The sample was concentrated using lyophillizer and trypsinized using 
the kit from Sigma. The sample was desalted using C18 tip. The final samples were sent to mass 
spectrophotometer for analysis. 
3.5.5 Immunoprecipitation 
HDFa membrane proteins were extracted using the membrane protein extraction kit. The 
membrane protein lysates were incubated with rPKM2 at room temperature for 2 hours and the 
PKM2 antibody was added into the lysate and incubated at 4 ˚C overnight. The protein G 
Agarose beads were added into the lysate and incubated at 4 ˚C for 2 hours. The beads were 
63 
collected by centrifugation at 13000 rpm and washed three times with PBS. The beads were 
resuspended in the sample loading buffer and boiled for 5 min. The samples were loaded for 
SDS-PAGE and later for western blot analysis. 
3.5.6 PI3K Activity Assay 
The PI3K activity was measured by ADP-Glo
TM
 Lipid Kinase Systems from Promega 
followed the instruction. Generally, the cells were inducted first with TGF-β or rPKM2 for two 
days and cell lysates were made using RIPA buffer. The lysates were pulled-down by Pi3K 
antibody and incubated with ATP and lipid substrate. The PI3K activity was measured by 
monitoring the increase of ADP level. 
3.5.7 PAK2 Activity Assay 
The PAK2 activity was measured by in vitro protein kinase reaction and then western 
blot to test the phosphorylation. The cells were inducted first with TGF-β or rPKM2 for two days 
and cell lysates were made using RIPA buffer. The lysates were pulled-down by PAK2 antibody. 
The in vitro protein kinase reaction consisted with PAK2 antibody pulldown lysate, 25 mM Tris 
pH 7.4, 10 mM MgCl2, 1 mM DTT, 5 µM ATP, and 5 µg of myelin basic protein. The reaction 
was preceded at 37 ˚C for 30 min. The reaction was stopped by adding loading buffer and boiled 
for 5 min. The samples were loaded for SDS-PAGE and phospho-myelin basic protein antibody 
was used in the western blot. 
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Figure 3.1 Identification of α-SMA in wound healing. 
(A). IF staining of α-SMA in wound skin. Frozen section of wound skin were cut and stained 
with α-SMA antibody in green. (B). Quantification of α-SMA staining. IF staining of α-SMA 
were quantified with ImageJ for the area of positive pixel. (C). Quantification of α-SMA staining 
in PKM2 antibody treated group. IF staining of α-SMA were quantified with ImageJ for the area 
of positive pixel. (D). Quantification of α-SMA in time series wound. Wound skin was collected 
at day 3, day 6 and day 8. Staining of α-SMA was quantified with ImageJ for the area of positive 
pixel. 
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Figure 3.1 Identification of α-SMA in wound healing. 
 
66 
Figure 3.2 Verification of myofibroblast and in vitro analysis of PKM2 effect on HDFa. 
(A). Verification of myofibroblast. Myofibroblast was verified with myosin and ER-TR7 
staining. (B). In vitro analysis of PKM2 effect on HDFa. Cell proliferation assay was analyzed 
with BrdU proliferation assay. Cell migration assay was analyzed with boydem chamber assay. 
Both assays were tested in buffer, rPKM1, and rPKM2 groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
A 
 
B C 
 
Figure 3.2 Verification of myofibroblast and in vitro analysis of PKM2 effect on HDFa. 
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Figure 3.3 Effect of PKM2 on HDFa. 
(A). In vitro analysis of PKM2 in HDFa differentiation. HDFa differentiation was induced with 
rPKM2 or TGFβ as positive control. Combination of rPKM2 and TGFβ was also applied. 
Western blot was performed to test α-SMA level. (B). IF staining of differentiated HDFa cells. 
rPKM2 and TGFβ were applied on HDFa cells. α-SMA was stained in green and phalloidin as 
actin indicator was stained in red. (C). Collagen level in culture media. Collagen level was test 
using antibody in Western blot. 
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Figure 3.3 Effect of PKM2 on HDFa. 
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Figure 3.4 Extracellular PKM2 activates integrin αvβ3 signaling. 
(A). Cell attachment assay of HDFa cells. rPKM2 and rPKM1 were coated on plate and HDFa 
cells were added in with αvβ3 antibody or BSA. (B). Immunoprecipitation of rPKM2 with HDFa 
membrane protein lysate. PKM2 antibody and IgG were used for IP. β3 antibody was used to test 
αvβ3 in the IP result. (C). The highlighted peptide fragments from trypsin digestion of rPKM2-
HDFa crosslinks and MALDI-tof/tof analyses that match the amino acid sequence of integrin 
αvβ3. (D). rPKM2 enhanced migration ability of HDFa was inhibited by αvβ3 antibody. 
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Figure 3.4 Extracellular PKM2 activates integrin αvβ3 signaling. 
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Figure 3.5 Extracellular PKM2 activates HDFa through integrin αvβ3.  
(A). Signaling pathway of extracellular PKM2 activating HDFa differentiation is independent of 
TGFβ pathway. TGFβ receptor inhibitor and TGFβ antibody were used to test the effect of 
rPKM2. P-Smad2 was used to represent as the classical signaling pathway of TGFβ. (B). αvβ3 
antibody eliminates the effect of rPKM2 on activation of α-SMA expression in HDFa. (C). FAK 
inhibitor reduces the effect of rPKM2 on activation of α-SMA expression in HDFa. 
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Figure 3.5 Extracellular PKM2 activates HDFa through αvβ3.  
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Figure 3.6 Extracellular PKM2 activates HDFa differentiation via PI3K. 
(A). PI3K activity is upregulated in the rPKM2 treated HDFa. TGFβ receptor inhibitor and FAK 
inhibitor was used as controls. (B). Phosphorylation of PAK2 was used as an indicator to test the 
downstream pathway of extracellular PKM2 activating α-SMA expression. (C). Inhibitor 
screening of extracellular PKM2 effect. PI3K inhibitor, Src inhibitor, and MEK inhibitor were 
tested. 
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Figure 3.6 Extracellular PKM2 activates HDFa differentiation via PI3K. 
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CHAPTER 4 EXTRCELLULAR PKM2 PLAYS A ROLE IN LIVER FIBROSIS 
4.1 Abstract 
Liver fibrosis is caused by chronic inflammation and activation of Hepatic Stellate Cells 
(HSCs). The resistance of HSCs to apoptosis is the main reason for non-reversal of liver fibrosis. 
However, the molecular mechanism of how activated HSCs are prevented from apoptosis is still 
not well understood. Here, we report that extracellular PKM2 exists in the liver tissue of liver 
fibrosis patients. Extracellular PKM2 promotes progression of liver fibrosis by protecting 
activated HSCs from apoptosis. PKM2 interacts with integrin αvβ3 on the cell surface of HSCs 
and activates FAK-PI3K pathway to stimulate survival signal. Neutralization of extracellular 
PKM2 by a specific antibody relieves the process of liver fibrosis. Our study uncovers a novel 
mechanism of activated HSCs survival during liver fibrosis. The positive effect of PKM2 
antibody treatment also suggests a possible therapeutic method for liver fibrosis. 
4.2 Introduction 
Liver fibrosis is the result of chronic liver damage which causes persistent inflammation 
at injury site. Inflammatory response continuously activates HSCs to differentiate into 
myofibroblast. Activated HSCs secret large amounts of extracellular matrix proteins that disrupt 
the architecture of liver tissue and restrains the normal liver function (Friedman, 2003). Liver 
fibrosis is considered “irreversible” because apoptosis of activated HSCs is reduced under the 
effect of chronic inflammation. However, a few studies have shown that low degree of liver 
fibrosis was reversible in certain circumstances. The study focusing on the apoptosis of activated 
HSCs is still the major target of liver fibrosis recover (Benyon & Iredale, 2000; Elsharkawy et al., 
2005). 
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The serum and stool level of PKM2 is highly correlated with several immune diseases 
with strong inflammatory response. In the previous study, we found that extracellular PKM2 
releases from activated neutrophils and facilitates wound healing by activating angiogenesis and 
granulation tissue formation. PKM2 activates myofibroblast differentiation through an integrin 
αvβ3-PI3K signal pathway.  
4.3 Results 
4.3.1 Identification of PKM2 in liver diseases 
To explore whether extracellular PKM2 plays a role in liver injury repair, we carried out 
IHC analysis of human liver disease tissue array using PKM2 antibody. High level of 
extracellular PKM2 was detected in viral hepatitis and liver cirrhosis (Figure 4.1 A). PKM2 level 
was gradually increased as the degree of liver disease progression. It showed a small increase in 
viral hepatitis samples, and had a significant increase in liver cirrhosis samples. As control, no 
PKM2 was detected in normal hepatic tissue sample. We classified the degree of staining into 
three categories, weak, medium, and strong. It showed that most of the normal hepatic tissue had 
weak PKM2 level, and viral hepatitis shifted to the medium level. Liver cirrhosis had huge 
increase in the strong category. (Figure 4.1 B). To confirm our tissue array analysis, we analyzed 
several freshly collected tissue samples from patients of liver cirrhosis. In consistent with the 
tissue array analysis, we observed strong extracellular PKM2 staining with tissue sample of liver 
cirrhosis, compared with normal hepatic tissue and viral hepatitis. The classified categories 
represented similar portion as in the tissue array (Fig. 4.1 C&D). ELISA assay of patient blood 
sample showed that PKM2 was detected in the blood circulation of patients with viral hepatitis 
and liver cirrhosis (Fig. 4.1 E). These results indicate that PKM2 is released to extracellular 
space of liver cirrhosis patients.  
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4.3.2 Extracellular PKM2 promotes liver fibrosis 
To study the function of extracellular PKM2 during liver fibrosis, a TAA/alcohol induced 
liver fibrosis mouse model was established. TAA/alcohol treatment is commonly used to induce 
liver fibrosis in mouse and rat model. TAA (Thioacetamide) is an organic molecule with sulfate 
group and is known as a potent centrilobular hepatotoxicant to induce liver injury with certain 
dosage (LD50, 300 mg/kg in mouse and rat). After administration of TAA, it undergoes a two-
step process from TAA to thioacetamide sulphoxide (TASO), and then thioacetamide-S, S-
dioxide (TASO2), which is an active metabolite. This process releases inducible nitric oxide 
synthase (iNOS) and nuclear factor-κB that causes apoptosis and necrosis (T. M. Chen et al., 
2008). Liver undergoes inflammation after injury caused by TAA. Long time treatment of TAA 
induces chronic inflammation and continuously activates HSCs to develop liver fibrosis. 
In our experiment, TAA was treated for two and a half weeks, and then buffer, rPKM1, 
and rPKM2 were added into the treatment respectively for three and a half weeks (Figure 4.2 A). 
Mouse body weight was measured though out the whole experiment. Starting from the injection 
of TAA at day 1, the average body weight of control group elevated compared with that of in the 
groups of TAA treatment. After rPKM2 was combined into the TAA injection, the body weight 
of TAA+rPKM2 group began to decrease and showed a significant difference at day 26. Body 
weights of TAA+rPKM2 group went to a steady level at day 34, and maintained a 2 grams 
difference compared with TAA+rPKM1 and TAA+buffer groups. Since the mice in control 
group kept growing, the final body weight difference between TAA and non-TAA groups was 5 
grams (Figure 4.2 B). After 6 weeks, livers were dissected and liver weight was measured. TAA 
treatment significantly increased liver weight, and the addition of rPKM2 had even more 
enhancement (Figure 4.2 C). Liver pictures were taken after six weeks of the treatment. TAA 
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treatment resulted in the increase of liver size. Some livers in TAA+rPKM2 groups had obvious 
bigger size compared with the livers in other groups (Figure 4.3 A) Close look of the liver 
surface showed typical fibrotic features on the liver of TAA treated groups. The liver from 
TAA+rPKM2 group had more white and yellow dots on the surface, considered as the typical 
liver fibrotic signs (Figure 4.3 B) 
4.3.3 Combination of rPKM2 and TAA causes more damage to liver function and 
architecture 
To study the liver function in different groups, serum markers (albumin, ALT, and AST) 
reflecting liver function were screened. In albumin test, TAA treatment significantly increased 
the serum level of albumin, but there was no difference between TAA+buffer, TAA+rPKM1, 
and TAA+rPKM2. In ALT and AST tests, TAA treatment had three-fold increase compared with 
control, and TAA+rPKM2 treatment doubled the effect of TAA treatment (Figure 4.4 A). To 
observe the architecture of liver tissue, we used Sirius Red to stain collagen in liver tissue. 
Control group did not have much collagen signal. Only a little was stained around blood vessels. 
TAA+buffer and TAA+rPKM1 groups showed increased collagen staining, that thin collagen 
bridges were formed between portal tracts. TAA+rPKM2 groups had extensive level of collagen 
with thick band and collagen bridges crossing portal tracts. (Figure 4.4 B) Quantification of 
collagen staining using FRIDA software revealed that TAA treatment induced the expression of 
collagen, and addition of rPKM2 resulted in dense collagen pattern and disrupted tissue structure 
(Figure 4.4 C). Other serum markers reflecting liver function were screened. All TAA treatments 
elevated the levels of cholesterol and total protein compared with control group.  
Only TAA+rPKM2 group had increased total bilirubin level (Figure 4.5 A). Liver 
fibrosis induces apoptosis of hepatocytes and generates apoptotic bodies in the liver tissue. The 
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number of apoptotic bodies is another way to analyze liver fibrosis. We stained the liver sections 
by H&E staining. The apoptotic bodies were marked with arrows. Control group did not have 
any apoptotic body, whereas TAA treatment damaged liver and showed typical apoptotic bodies 
in the liver sections. In addition, TAA+rPKM2 revealed more apoptotic bodies, indicating more 
damage to the liver tissue (Figure 4.5 B&C). 
To test whether extracellular PKM2 can induce liver fibrosis, rPKM2 treatment without 
injection of TAA was compared with TAA treatment and control. We performed the same 
procedure as in the previous model. rPKM2 only group did not have any change in body weight 
and liver weight compared to control group (Figure 4.6 A&B). The liver size in rPKM2 only 
group showed similar as in control group (Figure 4.6 C). Both rPKM2 only group and control 
group had no significant collagen staining compared with TAA+buffer group (Figure 4.6 D) 
4.3.4 Extracellular PKM2 protects activated HSCs from apoptosis  
Addition of rPKM2 to TAA treatment induced more activated HSCs in liver tissue, which 
was marked by α-SMA in red. Apoptotic cells around HSCs were stained in green with TUNEL. 
The number of apoptotic cells was decreased in the TAA+rPKM2 treatment (Figure 4.7 A&B). 
Given that HSCs apoptosis is involved in liver fibrosis, we questioned whether extracellular 
PKM2 can affect HSCs apoptosis to promote liver fibrosis. We first tested the effect of 
extracellular PKM2 in HSCs in vitro using MTT assay. Primary HSCs were purchased and 
cultured for at least 7 days to obtain α-SMA activation (Figure 4.7 C). FasL and TRAIL were 
applied to induce apoptosis which reduce the absorbance in MTT assay, but addition of rPKM2 
brought it back (Figure 4.7 D). Similar experiment was done using LX-2 cells also showed that 
rPKM2 treatment reduced the apoptotic level of LX-2 after TRAIL induction (Figure 4.7 E). 
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4.3.5 PKM2 interacts with integrin αvβ3 on the cell surface of HSCs 
Our laboratory found that extracellular PKM2 interacted with integrin αvβ3 on the cell 
surface of endothelial cells and HDFa cells. Activated HSCs has been shown to have enhanced 
integrin αvβ3 expression. We performed the same crosslinking experiment and mass 
spectrometry assay to detect what is the cell surface target of PKM2 on HSCs. Several protein 
bands were found in the crosslinked result (Figure 4.8 A). Integrin αvβ3 was identified (Figure 
4.8 B&C). We confirmed this interaction with PKM2 antibody pull-down assay and cell 
attachment assay with rPKM2 coated on the plate (Figure 4.8 D&E) 
4.3.6 PKM2 activates the survival signal of activated HSCs through integrin αvβ3, PI3K, 
and NFκB 
To pursue the interaction between PKM2 and integrin αvβ3, we added integrin αvβ3 
antibody to the MTT assay and found it disrupted the protecting effect of rPKM2 (Figure 4.9 A). 
Since FAK is the downstream pathway of integrin αvβ3, we then tested the effect of FAK 
inhibitor in the rPKM2 protection of LX-2 cell apoptosis. As expected, rPKM2 induced the 
viability of LX-2 cells back to normal level, but addition of FAK inhibitor eliminated its benefit 
(Figure 4.9 B). In the extracellular PKM2 activated HDFa case, we discovered that PI3K is 
activated. Since PI3K is an important factor in the survival signaling pathway, we revealed that 
PI3K was activated in LX-2 cells after treatment of rPKM2 and the activity was reduced when 
FAK inhibitor was added (Figure 4.9 C). Further apoptotic test found that PI3K inhibitor also 
disrupted the protection of rPKM2 for the TRAIL induced LX-2 cell apoptosis (Figure 4.9 D). 
NFκB is known as a downstream factor of PI3K mediated survival signaling pathway. We then 
examined whether NFκB play a role in the activation of PI3K by extracellular PKM2 in HSCs. 
NFκB activity was measured by NFκB transcription factor assay. rPKM2 treatment significantly 
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elevated the activity of NFκB compared with control. This activation was inhibited by both αvβ3 
antibody and PI3K inhibitor (Figure 4.9 E). 
4.3.7 Neutralization of extracellular PKM2 facilitates liver recovery from TAA/alcohol 
induced fibrotic damage 
Since PKM2 is found extracellularly during liver fibrosis, we wondered whether 
neutralization of extracellular PKM2 can relieve the liver tissue damage. To find the appropriate 
PKM2 antibody for animal experiment, we tested the blocking ability of PKM2 antibody in LX-
2 cell attachment assay. We first picked two antibodies recognizing only PKM2 but not PKM1 
(Figure 4.10 A).  We tested this pair of PKM2 antibody IgGPK16 and IgGPK21. IgGPK16 had 
very good effect of blocking the attachment of LX-2 cell on rPKM2 coated plate (Figure 4.10 B). 
This set of mouse liver fibrosis model was designed by treating TAA/alcohol for 12 weeks and 
then following 10 doses of PKM2 antibody and control antibodies (buffer, IgGCon, and 
IgGPK21) (Figure 4.10 C). Mouse body weights were measured through the experiment. During 
the 12-weeks of TAA/alcohol treatment, body weight of TAA treated groups was significantly 
lower compared with control group. After stop of TAA/alcohol treatment, body weight of 
IgGPK16 group had faster increase than other control groups (Figure 4.10 D). Final liver weights 
showed that buffer, IgGCon, and IgGPK21 group had about 0.5 g increase compared with 
control, and body weight of IgGPK16 group reduced close to control level (Figure 4.10 E).  
Liver pictures clearly showed the liver size of buffer, IgGPK21, and IgGCon groups were 
bigger than IgGPK16 group (Figure 4.11 A). Close examination of liver surface revealed bigger 
size and typical fibrotic feature in buffer group. IgGPK16 group had similar liver size and 
surface features compared to control group (Figure 4.11 B). To test the effect of PKM2 antibody 
in liver function and architecture, we did both serum marker screen and Sirius Red staining to 
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stain collagen. In the serum albumin level, all treatments had increased compared with control, 
and there was no difference among them. In the serum ALT and AST levels, all treatments also 
increased compared with control, but IgGPK16 treatment reduced ALT and AST levels after the 
whole experiment (Figure 4.12 A). In the Sirius Red staining result, buffer, IgGCon, and 
IgGPK21 groups presented dense collagen with network structure. On the other hand, IgGPK16 
group indicated reduction of collagen expression (Figure 4.12 B&C). In the H&E staining result, 
IgGPK16 treatment showed less numbers of apoptotic bodies indicating the relief of liver 
fibrosis (Figure 4.13 A). Double staining of α-SMA and TUNEL showed that IgGPK16 
treatment had less α-SMA expression but more apoptotic cells compared with IgGCon treatment 
(Figure 4.13 C). 
Previously, we reported that PKM2 can be released from infiltrated neutrophils during 
wound repair process. The released PKM2 promotes wound repair. Very similar to the case of 
cutaneous wound, liver injury would also trigger strong immune responses with neutrophil 
infiltration/activation. Thus, it is expected that high levels of infiltration neutrophils would be 
presented in fibrotic liver. Indeed, IHC staining of liver tissue array showed that neutrophils 
presented at high levels in liver cirrhosis tissue samples (Figure 4.14 A). The observation clearly 
supported the notion that activated neutrophils release PKM2. Extracellular PKM2 acts on 
integrin αvβ3 of HSCs to promote activated HSCs survival. A number of previous studies 
showed that activation of several pairs of integrin facilitates fibrosis progression, including αvβ6, 
αvβ8, and αvβ1. It is believed that the effects of these integrin pairs on fibrosis progression are 
mediated via activation of latent TGFβ. Thus, we asked whether extracellular PKM2 acted by a 
similar mechanism in facilitating liver fibrosis progression. We tested the effects 
neutralize antibody and a TGFβ receptor inhibitor on the activity of extracellular PKM2. Clearly, 
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the function of extracellular PKM2 was TGFβ signaling independent (Figure 4.14 B). 
Furthermore, TGFβ receptor was not activated in LX-2 cells upon rPKM2 treatment (Figure 4.14 
C). Cell attachment assays demonstrated that integrin αvβ6 and αvβ1 expressing CHO cells did 
not attach to rPKM2 coated plates (Figure 4.14 D), indicating that PKM2 did not interact with 
these integrins. 
4.4 Discussion 
We demonstrated that extracellular PKM2 promotes liver fibrosis by protecting activated 
HSCs from apoptosis. Our laboratory previously discovered that neutrophils releases PKM2 
activated myofibroblast differentiation of dermal fibroblasts via integrin αvβ3 signaling pathway. 
By interacting with the same target on cell surface, extracellular PKM2 stimulates different 
reactions in dermal fibroblasts and HSCs. We questioned what could be the reason of this 
alternative function. Is extracellular PKM2 also involved in the transformation from HSCs to 
myofibroblasts? Integrin αvβ3 signaling is involved in several pathways. Multiple factors can 
activate integrin αvβ3 in addition to its natural ligand vitronectin. We cannot exclude the 
function of PKM2 activating differentiation in HSCs during liver fibrosis. More tests related with 
myofibroblast differentiation of HSCs should be done in the future. 
PKM2 antibody treatment showed promising effect in the TAA/alcohol induced mouse 
fibrosis model. We questioned can PKM2 antibody treatment fully reverse liver fibrosis? In our 
experiment, after 12 weeks of TAA/alcohol treatment, PKM2 antibody was applied for 20 days. 
Body weight of IgGPK16 group was still about 2 grams smaller than control group. Extension of 
PKM2 antibody treatment might provide better result that IgGPK16 group can catch up control 
group. Collagen staining result showed that the IgGPK16 group still maintains certain amounts 
of collagen. The digestion of remaining collagen by MMPs would take longer time. In this 
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TAA/alcohol induced mouse liver fibrosis model, the stage of fibrosis was still considered in 
early or middle stage corresponding to the collagen staining pattern. At this stage, liver fibrosis 
could be still reversible, because of the high metabolism of mouse. Different mouse fibrosis 
models, such as CCl4, dimethylnitrosamine (DMN), bile duct ligation, and concanavalin A 
should be tested with PKM2 antibody treatment to confirm the effect of reversing fibrosis.   
4.5 Materials and Methods 
4.5.1 Liver fibrosis induction and treatments 
All animal experiments were carried out in accordance with the guidelines of IACUC of 
Georgia State University. Balb/c mice (6-7 week old male) were I.P. injected with 100 mg/kg 
TAA and gradually increased to 200 mg/kg TAA in two weeks. 10% alcohol was also fed to 
mice along with the TAA treatment. For rPKM2 experiment, 5 mg/kg of rPKM2 was mixed with 
TAA for injection starting at two and a half week, and lasted for total of seven weeks. TAA 
mixed with buffer or rPKM1 was the control. For the PKM2 antibody experiment, TAA was 
continuously treated for twelve weeks. After that, TAA and alcohol was stopped and 4mg/kg of 
PKM2 antibody was I.P. injected every other day for ten doses. Buffer and rabbit IgG was the 
control. The body weights were recorded every week or every four days. At the end of the 
experiments, animals were sacrificed. Livers, other organs, and blood samples were collected. 
Liver weights were measured and liver pictures were taken. Tissue sections were prepared and 
analyzed by IF, IHC, or H&E stains using commercially available antibodies as indicated. Serum 
samples were prepared from collected blood samples. The serum samples were analyzed by the 
service of Comparative Clinical Pathology.  
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4.5.2 Sirius Red staining and analysis for collagen 
Sirius Red staining was used the NovaUltra
TM
 Sirius Red Stain Kit from IHCWORLD. 
The staining procedure was basically followed the protocol provided in the kit. In brief, the 
paraffin embedded slides were deparaffinized in xylene, 100% alcohol, 95% alcohol, 70% 
alcohol, 50% alcohol, 30% alcohol, and then distilled water. The slides were stained in Weigert’s 
Hematoxylin Solution for 10 min, and washed with running tap water for 10 min. Then, the 
slides were incubated in Pico-Sirius Red Solution for one hour and followed with Acetic Acid 
Solution for 1 min. The cells were stained in light brown and collagen was stained in red. The 
slides were dehydrated through increased concentration of alcohol and mounted in a resinous 
mounting medium. The pictures of collagen staining were taken with microscope under X100 
magnification. The density of collagen staining was quantified using FRIDA software. 
4.5.3 MTT assay  
MTT assay was used to measured HSCs and LX-2 cell viability. MTT was dissolved at 5 
mg/ml in specific culture medium to make the stock solution. The solution was filtered through a 
0.22 μm filter before adding into the culturing cells. MTT stock solution was added to each well 
at a 1:10 dilution and incubated for 3 to 4 hours. At the end of the incubation period, the culture 
media were removed and acidic isopropanol was added into each well to solubilize the dye. 
Absorbance of solubilized dye was measured at a wavelength of 570 nm with background 
subtraction at 690 nm. 
4.5.4 NFκB transcription factor assay 
Activity of NFκB was measured by an NFκB p50/p65 EZ-TFA transcription factor assay 
kit. The flanked DNA binding consensus sequence for NFκB was coated on the plate. After 
incubation with cell extracts, activated NFκB was captured by the plate. The bound NFκB 
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transcription factor unit p50 and p65 were detected by specific antibodies similarly as in ELISA 
procedure.  
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Figure 4.1 Identification of PKM2 in liver diseases. 
(A) Immunohistochemistry staining of PKM2 in liver cirrhosis or hepatitis tissue microarray. 
Microarray is stained with PKM2 antibody. Samples are separated to three groups, normal 
hepatic tissue, viral hepatitis, and liver cirrhosis. (B) Quantification of PKM2 staining in 
microarray. PKM2 intensity is divided into three categories: weak (<2000), medium (2000-5000), 
and strong (>5000). Each core is examined and classified into one of the previous three 
categories. (C) IHC staining of PKM2 in hepatitis and cirrhosis patient liver samples. (D) 
Quantification of PKM2 staining fresh patient samples. PKM2 intensity is divided into three 
categories: weak (<2000), medium (2000-5000), and strong (>5000). Each section is examined 
and classified into one of the previous three categories. (E) Serum PKM2 levels of viral hepatitis 
and liver cirrhosis patients.  
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Figure 4.1 Identification of PKM2 in liver diseases. 
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Figure 4.2 Addition of PKM2 affects body weight and liver weight in the TAA/alcohol 
mouse model. 
(A) Liver fibrosis mouse model diagram. (B) Average mouse body weight through the treatment 
(6 weeks). (C) Average mouse liver weight at the end of the experiment.  
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Figure 4.2 Addition of PKM2 affects body weight and liver weight in the TAA/alcohol 
mouse model. 
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Figure 4.3 Addition of PKM2 promotes liver fibrosis in the TAA/alcohol mouse model. 
 (A) Liver pictures of different groups. (B) Liver zoomed-in pictures of control, TAA+buffer, 
and TAA+rPKM2 groups. 
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Figure 4.3 Addition of PKM2 promotes liver fibrosis in the TAA/alcohol mouse model.                          
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Figure 4.4 Addition of PKM2 deals more liver damage in the TAA/alcohol mouse model.  
(A). Serum marker analysis in different groups. (Albumin, ALT, and AST) (B). Sirius Red 
staining of paraffin embedded liver samples. Light brown color indicates background cell 
staining, and red color indicates collagen staining. (C) Quantification of Sirius Red staining for 
collagen.  
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Figure 4.4 Addition of PKM2 deals more liver damage in the TAA/alcohol mouse 
model. 
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Figure 4.5 Addition of PKM2 induces apoptotic body number in the TAA/alcohol mouse 
model. 
(A). Serum markers analysis in different groups (cholesterol, total protein, and total bilirubin). 
(B). H&E staining of paraffin embedded liver samples. Nucleus is stained in purple, and cytosol 
is stained in pink. Apoptotic bodies are marked with arrows. (C) Quantification of apoptotic 
bodies. 
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Figure 4.5 Addition of PKM2 induces apoptotic body number in the TAA/alcohol 
mouse model. 
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Figure 4.6 Treatment of PKM2 only does not induce liver fibrosis. 
(A) Mouse body weights through the treatment (rPKM2 only). (B) Mouse liver weights at the 
end of the experiment (rPKM2 only). (C) Liver pictures of different groups (rPKM2 only). (F) 
Sirius Red staining of paraffin embedded liver samples (rPKM2 only). 
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Figure 4.6 Treatment of PKM2 only does not induce liver fibrosis. 
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Figure 4.7 Extracellular PKM2 protects activated HSCs from apoptosis. 
(A) Immunofluorescence staining of frozen liver samples. Green color indicates TUNEL, and red 
color indicates α-SMA. (B) Quantification of α-SMA intensity vs numbers of TUNEL nucleus. 
(C) Immunoblot of α-SMA in HSCs before and after activation. (D) rPKM2 treatment protects 
HSCs from FasL and TRAIL induced apoptosis. (E) rPKM2 treatment protects LX-2 cells from 
TRAIL induced apoptosis.  
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Figure 4.7 Extracellular PKM2 protects activated HSCs from apoptosis. 
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Figure 4.8 PKM2 interacts with integrin αvβ3 on the cell surface of LX-2 cells. 
(A) SDS-PAGE of LX-2 cell membrane extract with or without crosslink. Arrows indicate 
possible integrin proteins. (B) Mass spectrometry analysis of digested protein bands showed 
integrin αv in the result. (C) Mass spectrometry analysis of digested protein bands showed 
integrin β3 and PKM2 in the result. (D) Attachment assay of LX-2 cells on different coatings. 
BSA or integrin αvβ3 antibody is pre-treated before the assay. (E) PKM2 antibody IP result of 
membrane extract of LX-2 cells.  
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Figure 4.8 PKM2 interacts with integrin αvβ3 on the cell surface of LX-2 cells. 
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Figure 4.9 PKM2 activates the survival signal of activated HSCs through integrin αvβ3, 
PI3K, and NFκB. 
(A) rPKM2 treatment protects LX-2 cells from apoptosis, which is disrupted by αvβ3 antibody 
in MTT assay. (B) FAK inhibitor diminishes the protection of PKM2 in LX-2 cell apoptosis in 
MTT assay. (C) PI3K activity assay of LX-2 cells. (D) PI3K inhibitor reduces the protection of 
PKM2 in LX-2 cell apoptosis in MTT assay. (E) NFκB activity assay. αvβ3 antibody and PI3K 
inhibitor decreases the NFκB activity induced by rPKM2 treatment in LX-2 cells. 
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Figure 4.9 PKM2 activates the survival signal of activated HSCs through integrin αvβ, 
PI3K, and NFκB. 
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Figure 4.10 Neutralization of extracellular PKM2 in the TAA/alcohol mouse model. 
(A) Attachment assay of LX-2 cells on rPKM2 coated plate with antibody blocking treatment. (B) 
Immunoblot of PKM2 antibody: IgGPK16 vs IgGPK21. (C) Diagram of liver fibrosis mouse 
model with antibody treatment (15 weeks). (D) Mouse body weights through the treatment. (E) 
Mouse liver weights at the end of experiment.  
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Figure 4.10 Neutralization of extracellular PKM2 in the TAA/alcohol mouse model. 
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Figure 4.11 Neutralization of extracellular PKM2 facilitates liver recovery from the 
TAA/alcohol induced fibrotic damage. 
(A) Liver pictures of different groups. (B) Liver zoomed-in pictures of control, buffer, and 
IgGPK16 groups.  
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Figure 4.11 Neutralization of extracellular PKM2 facilitates liver recovery from the 
TAA/alcohol induced fibrotic damage. 
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Figure 4.12 Neutralization of extracellular PKM2 recovers liver function from the 
TAA/alcohol induced fibrotic damage. 
 (A) Serum markers reflecting liver function (albumin, ALT, and AST). (B) Sirius Red staining 
of paraffin embedded liver samples. (C) Quantification of Sirius Red staining for collagen.  
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Figure 4.12 Neutralization of extracellular PKM2 recovers liver function from the 
TAA/alcohol induced fibrotic damage. 
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Figure 4.13 Neutralization of extracellular PKM2 affects apoptotic bodies and HSCs 
apoptosis in the TAA/alcohol mouse model. 
(A) H&E staining of liver sections. (B) Immunofluorescence staining of frozen liver samples. (C) 
Quantification of α-SMA intensity vs numbers of TUNEL nucleus. 
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Figure 4.13 Neutralization of extracellular PKM2 affects apoptotic bodies and HSCs 
apoptosis in the TAA/alcohol mouse model. 
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Figure 4.14 PKM2 activated integrin αvβ3 signal is independent of TGFβ signal. 
(A) Quantification of IHC staining of Ly6G in liver disease tissue microarray. (B) TGFβ 
antibody and TGFβ receptor inhibitor does not affect the activity of PKM2. (C) TGFβ receptor is 
not activated upon treatment of PKM2. (D) CHO cells expressing integrin αvβ3 attach to the 
rPKM2 coated plate, compared with integrin αvβ1 and αvβ6 expressions. 
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Figure 4.14 PKM2 activated integrin αvβ3 signal is independent of TGFβ signal. 
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Figure 4.15 Diagram of the whole process. 
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Figure 4.15 Diagram of the whole process. 
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CHAPTER 5 MATERIALS AND METHODS 
5.1 Materials 
5.1.1 Chemicals 
Acetic Acid  VWR international 
Acrylamide  VWR international 
Agar  Sigma Aldrich 
Agarose  Sigma Aldrich 
Ammonium Persulfate (APS) Sigma Aldrich 
Ampicillin  Sigma Aldrich 
ATP Sigma Aldrich 
Autoradiography film  Fisher Scientific 
Bacto Yeast Extract  BD Biosciences 
Bacto Tryptone  BD Biosciences 
Bis-Acrylamide (w/v 29:1) VWR International 
β-Mercaptoethanol  Sigma Aldrich 
Bromophenol Blue  EMD 
Calcium Chloride Sigma Aldrich 
Cell culture media  Cellgro 
Coomassie blue  Sigma Aldrich 
Crystal Violet Sigma Aldrich 
Dithiothreitol (DTT) Sigma Aldrich 
Dimethyl Sulfoxide (DMSO) Sigma Aldrich 
ECL Western Blot substrate  Thermo Scientific 
Ethanol, 200 Proof  VWR International 
Ethidium Bromide  Sigma Aldrich 
Ethylenediaminetetraacetic Acid (EDTA). Sigma Aldrich 
FAK inhibitor 14 Millipore 
Fetal Bovine Serum (FBS) Invitrogen Life Technologies 
Formaldehyde  Sigma Aldrich 
Formalin, 10% solution  Sigma Aldrich 
Glycerol VWR International 
Glycine  VWR International 
Hank's Balanced Salt Solution (HBSS) Invitrogen Life Technologies 
HEPES  Sigma Aldrich 
Hydrochloric acid  VWR International 
Imidazole  Sigma Aldrich 
Isopropyl Alcohol  VWR International 
Isopropyl ß-D-1-thiogalactopyranoside(IPTG) Sigma Aldrich 
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Kanamycin  Sigma Aldrich 
Magnesium Chloride  Sigma Aldrich 
Methanol  VWR International 
Nail Polish Fisher Scientific 
Ni-NTA agarose  Qiagen Inc. 
Penicillin-Streptomycin solution  Cellgro 
Phenylmethylsulfonyl Fluoride (PMSF) Sigma Aldrich 
Ponceau solution  Sigma Aldrich 
Potassium Chloride Sigma Aldrich 
Prolong gold anti-fade reagent with DAPI Invitrogen Life Technologies 
Protein A agarose  Thermo Scientific 
Protein G agarose  Millipore 
Protein inhibitor cocktail  Sigma Aldrich 
Phosphatase inhibitor cocktail I (Ser/Thr)  Sigma Aldrich 
Phosphatase inhibitor cocktail II (Tyr)  Sigma Aldrich 
RIPA buffer, 10X Millipore 
Sodium Acetate  Sigma Aldrich 
Sodium Chloride  VWR International 
Sodium Bicarbonate  Sigma Aldrich 
Sodium Dodecyl Sulfate  Sigma Aldrich 
Sodium Fluoride  Sigma Aldrich 
Sodium Hydroxide  Sigma Aldrich 
Sodium Pyruvate solution  Cellgro 
N,N,N’,N’-TetramethylEthylenediamine 
(TEMED) Sigma Aldrich 
Thiazolyl Blue Tetrazolium Bromide (MTT)  Sigma Aldrich 
Tris base  Fisher Scientific 
Triton X-100  Sigma Aldrich 
Trypan Blue solution  Sigma Aldrich 
0.25% Trypsin-EDTA  Cellgro 
Tween-20  Sigma Aldrich 
Western Blot Stripping Buffer  Thermo Scientific 
 
5.1.2 Kits 
Bio-Rad Protein Assay  Bio-Rad Laboratories 
Biocoat Cell Migration System  BD Bioscience 
Nuclear Extraction Kit  Active Motif 
QIAprep Spin Miniprep Kit  Qiagen Inc. 
QIAquick Gel Extraction Kit  Qiagen Inc. 
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Wizard® plus DNA purification System  Promega 
 
5.1.3 Laboratory Equipments 
7500 Fast Real-Time PCR System  Life Technologies 
Allegra 6R Refrigerated Benchtop Centrifuge  Beckman Coulter 
C25 Incubated Floor Shaker  New Brunswick Scientific 
Class II Biosafety Cabinet  Labconco 
EC3 BioImaging System  UVP 
Film Processor Kodak 
French Presure Cell Press Aminco 
Mastercycler Gradient  Eppendorf 
UV-1700 Spectrophotometer  Shimadzu 
Victor3 Multilable Plate Reader  Perkin Elmer 
 
5.1.4 Enzymes and Recombinant Proteins 
Alkaline phosphatase, Shrimp  Promega 
C-Abl protein tyrosine kinase  New England BioLabs 
DNase  Promega 
MBD3  BioClone 
Pfu-DNA polymerase  Promega 
Proteinase K  Sigma Aldrich 
PDGF-AA  Pepro Tech 
PDGF-BB  Pepro Tech 
RNase A  Thermo Scientific 
Restriction enzymes  Thermo Scientific 
T4 Polynucleotide Kinase  Promega 
T4-DNA ligase  Thermo Scientific 
YOP protein tyrosine phosphatase  New England BioLabs 
 
5.1.5 Antibodies 
β-Actin antibody (mouse monoclonal)  Santa Cruz Biotechnology 
E-cadherin (mouse, monoclonal)  BD Biosciences 
GAPDH antibody (mouse monoclonal)  Thermo Scientific 
HA antibody (mouse monoclonal)  Roche Applied Science 
HA antibody (rabbit polyclonal)  Lab generated 
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6x-His antibody (rabbit polyclonal)  Abcam 
Histone 2A (rabbit polyclonal)  Cell Signaling Technology 
 
5.1.6 Bacteria strains and mammalian cell lines 
BL21-CodonPlus (DE3)-RIL  Stratagene 
JM109  Promega 
Human Dermal Fibroblasts, adult (HDFA). Thermo Fisher Scientific 
LX-2 Human Hepatic Stellate Cell Line  Millipore 
Primary Human Stellate Cells (HSC). Zen-Bio, Inc. 
 
5.2 Methods 
5.2.1 Bacteria Culture 
Different types of E. coli were cultured in LB (Lysogeny broth) medium with 1% 
kanamycin at 37˚C and 250 RPM. JM109 was used for plasmid DNA duplication, BL21 (DE3)-
pLysS and Tuner were used for recombinant protein expression. For colony selection, agar plates 
were made with LB medium-kanamycin and 15 g/L agar. For strain storage, the transformed 
bacteria were mixed with sterile glycerol (30% (v/v)) and stored at -80˚C. 
5.2.2 Transformation 
To prepare the competent cells, single clone of bacteria strain was inoculated from the 
plate to a 25 mL LB culture medium and shook at 37 ˚C overnight. The culture medium was then 
centrifuged at 4 ˚C 5000 rpm for 20 min. The cell pellet was resuspended in sterile CaCl2 and 
centrifuged again. The cell pellet was resuspended in sterile water and aliquot to save in -80 
aliquot. 
For transformation, the competent cells were thawed on ice. The plasmids were add into 
the cells and incubated on ice for 5 min. The mix was then transfer to 42 ˚C water bath to 
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incubate for 90 seconds, and then on ice for 2 min. 500 μL of LB medium was added into the 
mix and shaking incubate at 37 ˚C for 1 hour. After incubation, the mix was spread on the plates 
using spatula.  
5.2.3 Protein Purification 
Cells were inoculated from one colony (or 10 µL stored cells) and shaking cultured in 5 
mL LB with 0.1 % kanamycin at 37 °C overnight. Cells were transferred into 1 L LB medium 
with 0.1 % kanamycin and shaking cultured for 3 to 5 hours at 37 °C to reach OD600 of 0.4. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to reach 1 mM and incubated at 16 °C 
overnight. Cells were harvested by centrifugation at 4 °C, 7000 rpm for 15 min. Cell pellets were 
resuspended in buffer A (50mM Tris, pH 7.5, 0.1M KCl, 25mM MgCl2, 20% glycerol, 2 mM 
DTT, and PMSF) and then lysed by french press. The lysates were centrifuged at 4 °C, 14000 
rpm for 30 min. The supernatants were collected and filtered for protein purification. For protein 
purification, PKM2 was fused with his-tag, therefore Ni
2+
 column was used to purify the protein 
in FPLC. After purification, protein in tubes were collected and dialysis with buffer A overnight 
at 4 °C. The purified protein was tested using SDS-PAGE. 
5.2.4 Antibody Generation and Purification 
The hybridoma with rabbit monoclonal PKM2 antibody production was generated by 
Epitomics, Inc. Hybridoma was thawed in warm RPMI1640 medium with Epitomics' rabbit 
hybridoma supplement A, 55 µM β-mercaptoehanol cell culture grade, and 10 % FBS in a 10 cm 
petri-dish. The medium was changed every day until cells reached 80 % confluency. The cells 
were trypsinized and cultured in T175 flask, then gradually moved to a 1 L cell culture bottle. To 
stimulate the antibody production, culture medium was switch from RPMI1640 to serum-free 
medium (Irvine scientific IS MAB-CD with 1% antibiotic/antimycotic, and 1% Glutamax). The 
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cells were culture in serum-free medium for 7 to 10 days. To harvest the antibody, the cells 
suspension was centrifuged at 4 °C, 3000 rpm for 15 min. The supernatant was collected for 
antibody purification.  
The rabbit monoclonal PKM2 antibody was purified using Protein G Agrose beads at 4 
°C. The beads was packed into a column, and washed with ten column volumes of cold PBS. 
The supernatant containing antibody was loaded in the column, and then washed with ten 
volumes of cold PBS. The antibody was eluted with 50 mM glycine pH 2.7 into 1 mL fractions 
containing the neutralization buffer (1M Tris, pH 8.0, 1.5 M NaCl, 1 mM EDTA).. Bradford 
protein assay was used to measure the antibody concentration in each fraction. The high 
concentration fractions were mixed, filtered, and aliquoted. 
5.2.5 Cell Proliferation Assay 
BrdU assay was used to measure cell proliferation. Cells were seeded into 96 well plate at 
about 10
5
 cells per well. Blank (no cells) and background (no BrdU label) controls were 
established. BrdU label was diluted 1:2000, and 20 μL of it was added into each well. The cells 
were incubated with BrdU label for 24 hours in the cell culture incubator. The wells were 
emptied and refilled with 200 μL Fixative/Denaturing Solution, and then incubated at room 
temperature for 30 min. The cells were incubated with diluted Anti-BrdU Antibody at room 
temperature for 1 hour. After washing three times with Wash Buffer, the Peroxidase Goat Anti-
Mouse IgG HRP Conjugate was diluted and added into each well to incubate at room 
temperature for 30 min. The cells were washed again three times with Wash Buffer, and 
incubated with Substrate Solution in the dark for 15 min followed with Stop Solution. The 
readings were recorded at wavelength of 450 nm. 
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5.2.6 Boyden Chamber Assay 
The cells were cultured in good condition and prepared for the migration assay. 24-well 
plate was used and fitted chambers were inserted into each well. 2 mL of culture medium with 
10% FBS was added into each bottom well. The cells were resuspended into serum-free culture 
medium. Each well was added with 2 x 10
4
 cells. rPKM2 or other reagents were added into the 
upper chamber as well. The plate was incubated in the incubator for 16 hours. After incubation, 
the chambers were washed three times with PBS and stained with crystal violet for 3 min. The 
wells were then washed and observed under microscope. 
5.2.7 SDS-PAGE 
The SDAS-PAGE gel was prepared before electrophoresis. The separating gel was first 
set up at bottom with 6~12% acrylamide, 0.375M Tris-HCl pH 8.8, 0.1% SDS, 0.04% APS, and 
0.08% TEMED). 1 mL of water was added on the separating gel to help it to polymerize firmly. 
While waiting for polymerization of the separating gel, the stacking gel was prepared with 5% 
acrylamide, 0.125M Tris-HCl pH 6.8, 0.1% SDS, 0.05% APS, and 0.15% TEMED. The stacking 
gel was poured onto the separating gel and the comb was inserted to generate wells. The lysates 
were diluted with 5X loading buffer (175 mM Tris-HCl pH 7.0, 5 mM EDTA, 10% SDS, 20% 
sucrose, 0.01% bromophenol blue, and 28.8 mM β-mercaptoehanol) and boiled for 5 min. The 
samples and protein ladder were loaded in the wells. The gel was ran at constant voltage 60 V 
first at the stacking stage, and then increased to 80 V at the separating stage. 
5.2.8 Western Blot 
The protein samples were separated by SDS-PAGE. Proteins were transferred from gel to 
a nitrocellulose membrane at constant current of 80 mA for 2 hours. The membrane was blocked 
in 5% BSA solution (5% BSA in TBST (20mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween-
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20)) at room temperature for 30 min. The membrane was washed with TBST three times, each 
time 5 min. The primary antibody was diluted in the 5% BSA solution. The membrane was 
incubated in it on a flat shaker at 4 ˚C overnight, and then washed three times again with TBST. 
The membrane was incubated with appropriate secondary antibody against the primary with a 
dilution of 1:2000 at room temperature for 30 min and followed with three times wash with 
TBST. The signal was detected with chemiluminescence reagents and developed in dark room. 
5.2.9 ELISA (enzyme-linked immuno assay) 
ELISA was performed using ELISA 96-well plate. PKM2 antibody was first coated on 
the plate at 4 ˚C overnight. Culture medium or serum were added into the plate and incubated at 
room temperature for 2 hours. The plate was washed twice with PBST and then incubated with 
detect antibody at 4 ˚C overnight. The plate was washed three times with PBST and followed 
with secondary antibody treating at room temperature for 1 hour. TMB substrate solution was 
added into the plate and incubated for 30 min. The reaction was terminated with adding stop 
solution. The reading was recorded with spectrophotometer at wavelength 450 nm. 
5.2.10 Preparation of Plasmid DNA 
Purification of DNA plasmid from bacteria was using QIAprep Spin Miniprep Kit. 2 mL 
of bacteria medium was inoculated with single colony from an agar plate, and then shaking 
incubated at 37 ˚C overnight. The cell pellet was generated by centrifuging at 5000 rpm for 5 
min and the supernatant was removed. The cell pellet was suspended in 250 µL of suspension 
buffer supplemented with RNase A, and followed by adding 250 µL alkaline lysis buffer to lyse 
the cells. After the lysate was adjusted to high-salt binding condition, the protein precipitation 
was showed up and removed by centrifugation at 13000 rpm for 10 min. The supernatant 
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containing DNA was applied to the QIAprep column, and washed for several times. The plasmid 
DNA was eluted by adding 50 µL of elution buffer and centrifugation. 
5.2.11 Quantification of DNA Concentration 
Concentration of DNA was determined by spectrophotometer at the wavelength of 260 
nm. One unit of OD260 equated to 50 µg/mL of double-stranded DNA. The ratio of OD260 to 
OD280 provided the purity of the DNA sample. If the ratio of OD260 to OD280 was higher than 
1.8, the sample was considered as pure DNA. 
5.2.12 Preparation of Whole Cell Lysates 
After treatments, cells were washed three times with ice-cold PBS. RIPA buffer 
supplemented with protease inhibitors cocktail was used to lyse the cells. The cells attached on 
the plate were added with RIPA buffer and scraped off with a rubber scraper or pipette tip. The 
lysates were transferred into a microtube and vortexed for 10 seconds. The lysates were then 
rotated at 4 ˚C for 30 min, and centrifuged at 13000 rpm at 4 ˚C for 15 min. The supernatants 
were stored at -20 ˚C freezer. 
5.2.13 Quantification of Protein Concentration 
The protein concentration in cell lysates and tissue homogeneous were measured by Bio-
Rad protein assay. A standard curve was generated using gradient concentrations of BSA 
standard. To measure the protein concentration, 10 μL of lysates was mixed with 790 μL water 
and 200 μL of Bio-Rad dye in a cuvette. The absorption readings were recorded with a 
spectrophotometer at wavelength 595 nm. Each absorption reading was plotted into the BSA 
standard curve to calculate the protein concentration. 
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5.2.14 Immunofluorescence Staining 
The frozen section slides were fixed in 95% ethanol and the extra gel was cleared. The 
samples were circled with PAP pen and blocked with 5% BSA solution at room temperature in 
humidity box for 30 min. The slides were incubated with primary antibody with 1:500 dilutions 
in 5% BSA solution at 4 ˚C overnight. The slides were washed with PBST three times each time 
5 min and then incubated with secondary antibody conjugated with fluorescence dye at room 
temperature for 30 min. If another fluorescence dye was needed, the slides were incubated with 
another primary antibody at room temperature for 2 hours and secondary antibody conjugated 
with fluorescence dye for 30 min. The slides were washed and mounted with Prolong Gold 
Antifade Mountant with DAPI. The coverslip was sealed by nail polish. The results of 
immunofluorescence staining were acquired by using Zeiss LSM 700 Confocal. 
5.2.15 Quantification of IF Staining 
IF staining was quantified using ImageJ software. The fields were chosen randomly from 
each group. Micro-vesicular density (MVD) and total positive area were quantified. MVD was 
measured by counting the positive staining point in each field. Total positive area was measured 
by selecting the positive staining pattern and calculating the area of each pattern. 
5.2.16 Immunohistochemistry (IHC). Staining 
IHC staining was performed following the protocol in Dr. Shi-Yong Sun’s lab in Emory. 
Generally, the slides were baked at 60 ˚C for 2 hours, and then hydrated by continuously 
incubating in the following solution in order (three times xylene, twice 100% ethanol, 90% 
ethanol, 70% ethanol, 50% ethanol, 30% ethanol, and distilled water). The antigen retrieval was 
done by incubating in 10 mM Sodium Citrate buffer pH 6.0 and microwaved for 5 min in high 
and 10 min in low. After the slides were cooled down to room temperature for 39 min, they were 
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washed with PBS for 5 min. The slides were incubated with Dual Endogenous Enzyme Block at 
room temperature for 30 min and wash again. The slides were incubated with primary antibody 
diluted in antibody diluents 1:500 at 4 ˚C overnight. The slides were washed with PBST twice 
and PBS once. The slides were treated with Labeled polymer-HRP at room temperature for 30 
min, followed by the same washes. Substrate chromogen solution was made by mixing 1 mL of 
DAB+ substrate buffer plus 1 drop of DAB+ chromogen. The slides were added by DAB+ 
solution and monitored under microscope. The slides were counter stained with hematoxylin QS 
for 1 min. The slides were dehydrated by reversely incubating from distilled water to xylene. The 
slides were mounted and sealed with nail polish. 
5.2.17 Quantification of IHC Staining 
Quantification of IHC staining was done by using FRIDA (FRamework for Image 
Dataset Analysis) software. All images ready to be analyzed were saved in the same folder. A 
mask was selected by picking positive signals in different images. After the mask was well 
defined, the software would calculate the area of expression pattern in other images. The results 
from different groups were compared.ng the area. 
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CHAPTER 6 CONCLUSIONS AND DISCUSSIONS 
6.1 Extracellular PKM2 released from neutrophils facilitates wound healing by 
promoting angiogenesis 
Wound healing is a slow and complicated process that every step needs to organize well 
for a proper recover. Since extracellular PKM2 promotes angiogenesis during tumor progression, 
and angiogenesis is critical for the proliferation stage of wound healing, we study wound repair 
with a mouse cutaneous wound model by topical application of rPKM2. Our results showed that 
topical application of rPKM2 facilitates wound closure. Immune staining analysis using CD31 
antibody found that topical application of PKM2 stimulates the growth of microvessel during 
wound healing.  
In mouse cutaneous wound model, the wound in rPKM2 treated group started to close 
rapidly at day 3 compared with the wounds in control groups. However, the wound sizes in all 
three groups were similar at day 8. What could be the reason of slower closure in the rPKM2 
treated group after day 6? Since the wound pictures only showed the outside of mouse skin 
recovery which is called re-epithelization, the outside appearance does not reflect the whole 
process of wound repair. To examine what happen inside the wound site, we examined the 
wound underneath of mouse skin. The rPKM2 treated group showed more established capillary 
vessel structure and granulation tissues, compared with those in buffer and rPKM1 treated 
groups. We thought that the topical application of rPKM2 facilitated the wound healing process 
by promoting the angiogenesis in proliferation stage, which led to faster repair at day 3. Given 
that the re-epithelization process is paralleled with angiogenesis and granulation tissue 
formation, other factors slowed down the closure of wound in rPKM2 treated group to insure a 
well-organized wound repair. It is also possible that the capillary structure in rPKM2 treated 
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group might be excessive compared with those in normal wound repair. As it is known that the 
process of wound healing needs to be regulated in an ordered manner. Angiogenesis and 
formation of granulation tissue should be stopped at a certain time point. It was possible that 
angiogenesis was extended due to addition of rPKM2 at day 6 in our experiment. To find a better 
way of applying rPKM2 in the cutaneous wound healing, we should design a strategy to apply 
rPKM2 at different time points to find the best fit for facilitating wound healing. This strategy 
may lead to proper growth of granulation tissue. 
In addition to the effect on angiogenesis, topical application of rPKM2 was also found to 
promote growth of granulation tissue underneath the skin wound. Is the growth of granulation 
tissue directly stimulated by extracellular PKM2 or by the PKM2 induced angiogenesis? At the 
beginning, angiogenesis is very important for proliferation stage to support granulation tissue 
growth. Thus, we believed that topical application of rPKM2 promoted angiogenesis, and the 
newly grown capillary brought more nutrients to support the growth of granulation tissue. 
However, we measured the thickness of granulation tissue and stained the fibroblast at the 
wound site. The results suggested that rPKM2 might play a role on dermal fibroblasts during 
cutaneous wound. I will discuss it in the second section of this chapter. 
We discovered that endogenous PKM2 located in extracellular space at the wound site by 
IHC staining of PKM2. Presence of PKM2 in the extracellular space of wound tissues suggested 
a possible intrinsic mechanism of secretion of PKM2 during the wound repair process. Due to a 
close correlation between neutrophils and PKM2 in a numbers of inflammatory diseases, we 
performed a time course of staining of neutrophils and PKM2 during cutaneous wound healing. 
Both neutrophils and PKM2 exhibited a similar timing of appearance peaked around day 3. It is 
known that neutrophils express PKM2. Thus, we isolated neutrophils from mouse bone marrow 
131 
and activated by fMLP. PKM2 was detected in the culture medium of activated neutrophils. The 
release of PKM2 was inhibited by several degranulation inhibitors. To prove that extracellular 
PKM2 is released from neutrophils in vivo during wound healing, we used beige mouse that 
carries deficiency of neutrophil migration. Both neutrophils and PKM2 were not presented at the 
wound site of beige mice. Neutrophils and PKM2 were found at wound site in the normal mice. 
Therefore, we concluded that extracellular PKM2 was released from activated neutrophils during 
wound healing.  
In the future study, we would like to answer two questions. The first question is how 
PKM2 is released from activated neutrophils. In cancer cells, reports suggested that PKM2 is 
secreted from exosome. One proteomics study stated that PKM2 locates at the primary and 
secondary granules. We found release of PKM2 correlated with the degranulation of neutrophil. 
Degranulation activator fMLP and damnacanthal stimulated the release of PKM2. We thought 
that PKM2 might interact with some granule proteins in the primary and secondary granules. 
Screening of different degranulation inhibitors showed partial effects of all tested inhibitor 
individually. To test which type of granule releases PKM2, we can co-stain PKM2 with the 
cargo protein in granules to find the transportation pathway. Electron microscopy is another 
method to study the transportation of PKM2. The second question is do other types of immune 
cells release PKM2? PKM2 is reported to be expressed in platelets, neutrophils, macrophages, 
and lymphocytes. (Hapa et al., 2011) As an example, it is possible that PKM2 is released from 
macrophages to promote angiogenesis. We stained wound tissue sections with antibody against 
one of macrophage markers F4/80 at day 2 of wound. No staining of macrophages was observed 
compared with high level staining of Ly6G and PKM2. To see the correlation at late time points, 
the samples from later stage of wound should to be stained with F4/80 and PKM2. Isolating 
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monocytes and activating them is another way to test whether PKM2 is release from 
macrophages in vitro. 
If extracellular PKM2 released from neutrophils facilitates wound healing, then 
neutralization by PKM2 antibody should affect the wound repair process. We designed another 
experiment with mouse cutaneous wound model by injecting PKM2 antibody and followed by 
the similar process in the previous experiment. The healing of wound was slowed down in the 
PKM2 antibody treated group compared with buffer and IgG controls. The micro-vessels were 
also limited in the PKM2 antibody treated group.  
In brief, our study revealed an unexpected role of extracellular PKM2 in facilitating 
wound healing by promoting angiogenesis. Release of PKM2 through degranulation of activated 
neutrophils suggested a new and important link between immune response and proliferation 
phase. This link provided an explanation of how neutrophil infiltration triggers early 
angiogenesis during wound healing which indicated a physiological role of neutrophils in 
addition to the anti-microbial function. 
6.2 PKM2 promotes myofibroblast differentiation via integrin αvβ3 
During the mouse wound healing experiment, we discovered that the granulation tissue of 
PKM2 treated group was much thicker than those of control groups. We thought only by 
promoting angiogenesis was not enough to stimulate the growth of granulation tissue. 
Extracellular PKM2 released from activated neutrophils may play a role in fibroblast. Dermal 
fibroblasts expressed high levels of integrin αvβ3. Myofibroblast differentiation is a key feature 
during granulation tissue formation. Clearly, α-SMA, the myofibroblast marker, was upregulated 
in the rPKM2 treated group during the wound healing.  
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We questioned how extracellular PKM2 triggered the upregulation of α-SMA in 
fibroblasts at the wound site. First, we tested the effect of extracellular PKM2 on HDFa cell 
proliferation and migration. PKM2 did not exhibited any effect on HDFa proliferation, but 
rPKM2 treated HDFa had significant increase in migration. Thus, we believed that extracellular 
PKM2 at wound site activated migration of dermal fibroblasts and recruited more of fibroblasts 
to the wound site. We subsequently tested the effect of extracellular PKM2 on HDFa 
differentiation, and compared the effects of TGFβ, the well-known myofibroblast differentiation 
activator. Surprisingly, rPKM2 independently induced the expression of α-SMA in fibroblasts. 
PKM2 is as effective as TGFβ in inducing α-SMA expression in fibroblasts. Combination of 
rPKM2 and TGFβ had an enhanced effect on α-SMA expression. Both rPKM2 and TGFβ treated 
HDFa demonstrated a typical feature of differentiated myofibroblast with stress fiber bundles 
and collagen secretion. To further test whether the activation of fibroblast by rPKM2 is 
independent of TGFβ, TGFβ antibody was added to neutralize residue TGFβ and TGFβ receptor 
inhibitor was also employed to inhibit the downstream signal pathway. The effect of TGFβ in the 
presence of antibody and inhibitor was reduced, whereas the effect of rPKM2 was not affected. 
Therefore, we concluded that extracellular PKM2 independently stimulates HDFa cell migration 
and differentiation. 
Several questions were raised regarding the promotion of HDFa differentiation by 
extracellular PKM2. Is PKM2 itself enough to activate full differentiation of myofibroblast? 
Mechanical force and other factors can partially activate myofibroblast differentiation. TGFβ is 
required for fully activation of myofibroblast differentiation. α-SMA expression, collagen 
secretion, fibers bundle, and cell contractile ability are used to analyze the degree of 
differentiation. In our study, rPKM2 independently induced expression of α-SMA and secretion 
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of collagen. However, rPKM2 induced less α-SMA expression and collagen secretion compared 
with that of TGFβ treatment. In a confocal microscopic study of co-stain α-SMA with actin, both 
rPKM2 and TGFβ treatments had increased spreading morphological change, increased α-SMA 
expression, and α-SMA/actin bundles (yellow). To study the contractile ability of HDFa, we can 
use collagen gel contraction assay that functionally tests the degree of myofibroblast 
differentiation. 
Our laboratory previously found that extracellular PKM2 interacted with integrin αvβ3 
and activated integrin signaling in endothelial cells. Since HDFa also have integrin αvβ3 
expression, it is highly possible that integrin αvβ3 is the target of extracellular on HDFa. We 
performed chemical crosslinking followed by mass spectrometry analysis. We found that integrin 
αvβ3 interacted with PKM2. Immunoblot of PKM2 pull-down further confirmed that integrin 
αvβ3 was the target of extracellular PKM2. Attachment assay with plate coated with rPKM2 
showed the interaction between PKM2 and integrin αvβ3 was blocked by LM609, an integrin 
αvβ3 antibody. To test the downstream signaling pathway of PKM2-αvβ3 in myofibroblast 
differentiation, we used several different inhibitors that inhibit the downstream protein kinases of 
FAK. PI3K was found to be the major target. Furthermore, rPKM2 induced the activity of PI3K 
in HDFa. Additional tests following PI3K demonstrated that PAK2 was the downstream pathway 
in stimulating α-SMA expression. 
Is integrin αvβ3 the only target of extracellular PKM2 in HDFa? One group reported that 
PKM2 interacts with tumor endothelial factor 8 (TEM-8) on tumor endothelial cells. Our 
laboratory observed that PKM2 interacted with integrin αvβ3 on endothelial cells. PKM2 
interacted with TEM-8 weakly. In the mass spectrometry analysis of PKM2 interacting partners, 
we identified several other proteins, including G3P, Hexokinase-1, ATP synthase, multiple 
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coagulation factor deficiency protein 2, myosin regulatory light chain 12B, filamin-A, α-actinin, 
tubulin, and HNRNP, could be PKM2 interacting proteins. These proteins can be separated into 
several groups, such as glycolytic enzymes, skeleton proteins, and cell transportation proteins. 
Apparently, none of these identified proteins located on the cell membrane. In our test, integrin 
αvβ3 was the only cell surface receptor identified in mass spectrometry. If other membrane 
targets exist, more detailed and specific mass spectrometry method should be applied in the 
future. 
TGFβ activates myofibroblast differentiation through TGFβ receptor and Smad family 
pathway. Activation of fibroblast differentiation by PKM2-integrin αvβ3 interaction was 
independent of TGFβ pathway. Do these two signal pathways crosstalk? TGFβ up-regulated the 
expression of integrin αvβ3 in fibroblasts, endothelial cells, and cancer cells. TGFβ cooperated 
with integrin to form a feedforward loop to induce integrin expression. In addition, TGFβ 
activated integrin ligands, including vitronectin, fibronectin, laminin, and collagen. TGFβ was 
also involved in the activation of integrin “inside-out” signaling. On the other hand, integrin can 
regulate TGFβ activation. Integrin αvβ3 associates with TGFβ receptor II, and activates the 
expression of TGFβ receptor I&II in lung fibroblasts. The latent form of TGFβ needs to be 
cleaved to generate active TGFβ. Integrin αvβ3 acts as a docking site for MMP2 and MMP9, 
which are the proteases responsible for latent TGFβ activation. In our study, TGFβ and PKM2 
shared a similar PI3K pathway of activating myofibroblast differentiation.  
If both TGFβ and PKM2 exist in the wound site at early time, it is interesting to ask 
which one plays the major role in activating myofibroblast differentiation. In wound healing, the 
major sources of TGFβ are from platelets and macrophage, whereas PKM2 is released from 
neutrophils. Although the level of extracellular PKM2 at neutrophil infiltration peak can be very 
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high, the activation of myofibroblast differentiation by TGFβ is still stronger due to its high 
efficiency. If TGFβ is the major stimulator, then what is the role of extracellular PKM2? The 
possible work flow could be that TGFβ and mechanical tension partially induces the 
myofibroblast differentiation at early time of inflammation. High level of extracellular of PKM2 
released from neutrophils interacts with integrin αvβ3 on the fibroblast surface which is induced 
by TGFβ stimulation. This interaction further facilitates the differentiation process. Thus, TGFβ 
can fully activate myofibroblast differentiation under the help of PKM2 activated integrin αvβ3 
pathway. 
In summary, our data demonstrated that extracellular PKM2 independently promoted 
myofibroblast differentiation by activating integrins αvβ3 on cell surface of dermal fibroblasts. 
In this regard, our discovery may uncover a new target that may help to develop therapeutic 
strategies in facilitating wound repair. TGFβ is considered as the major stimulator which 
activates myofibroblast differentiation that provides early collagen deposition and granulation 
tissue formation. However, several studies have shown that TGFβ activation was not the only 
one for myofibroblast differentiation. We suggested that release of PKM2 from activated 
neutrophils at wound site replaced and strengthen the effect of TGFβ for myofibroblast 
differentiation during wound healing.  
6.3 Extracellular PKM2 prevents apoptosis of activated hepatic stellate cells during liver 
fibrosis 
Liver fibrosis is induced by chronic liver damage and inflammation. Neutrophils infiltrate 
to the damaged area and release large amount of PKM2. To study the function of extracellular 
PKM2 in liver fibrosis, we established a TAA/alcohol mouse model with rPKM2 after two and a 
half weeks. The body weight was reduced in the TAA treated fibrotic mice, further decreased 
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with addition of rPKM2. After TAA+rPKM2 treatment, both weight and size of liver were 
increased compared with controls. Typical fibrotic feature was seen on the surface of those 
livers. Serum marker screening showed that fibrosis induction by TAA/alcohol treatment 
increased albumin, ALT and AST level in the blood. Addition of rPKM2 further increased serum 
ALT and AST level. Sirius Red staining was used to examine the liver collagen contents. 
TAA+rPKM2 treatment showed intensive collagen levels and thick collagen cross networks. 
HSCs apoptosis is related to liver fibrosis progression. We found that TAA+rPKM2 
treatment had increased α-SMA and reduced apoptosis that indicated function of extracellular 
PKM2 in protecting HSCs from apoptosis. In vitro study showed that rPKM2 relieved the 
apoptotic stress of HSCs and LX-2 cells from FasL and TRAIL induced apoptosis. rPKM2 
interacted with integrin αvβ3 on the cell surface of activated LX-2 cells. Integrin αvβ3 activated 
FAK, and PI3K to stimulate survival signal of HSC. Neutralization of extracellular PKM2 using 
a specific antibody against PKM2 in TAA/alcohol liver fibrosis mouse model reduced liver 
fibrosis progression. The collagen staining of IgGPK group showed less signal and very thin 
collagen cross networks. 
Our study revealed an unexpected role of extracellular PKM2 in facilitating liver fibrosis 
progression by protecting activated HSCs from apoptosis. Reverse of liver fibrosis is the most 
important task in the treatment of cirrhosis. HSCs apoptosis is a key to prevent progression of 
liver fibrosis. Our results showed that antibody against PKM2 that disrupt the PKM2-integrin 
αvβ3 interaction are very effective in reversing liver fibrosis in TAA/alcohol mouse model, 
indicating a potential anti-fibrotic strategy and target.  
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6.4 Physiological and pathological functions of extracellular PKM2 
PKM2 is the enzyme acting at last step of glycolysis converting PEP to pyruvate. The 
default function of PKM2 is same as other pyruvate kinases in glycolysis. However, the pyruvate 
kinase activity of PKM2 is lower compared with that of other isoenzymes. PKM2 is expressed in 
highly proliferating cells, suggesting a unique function related to proliferation. Slow glycolysis 
rate caused by low pyruvate kinase activity of PKM2 results in the accumulation of 
intermediated materials which in favor of proliferation. In the recent study, function of PKM2 
involving in cancer cell proliferation was highlighted in cell nucleus. PKM2 translocates into 
nucleus and acts as protein kinase to phosphorylate histone H3 and STAT3 to promote 
proliferation. PKM2 also binds with HIF1 to regulate β-catenin. 
PKM2 has two conformations existing in the cells, dimer and tetramer. Tetrameric PKM2 
has higher affinity to substrate PEP and better pyruvate kinase activity, whereas dimeric PKM2 
shows low pyruvate kinase activity due to weak affinity to PEP. In metabolic pathway, pyruvate 
kinase catalyzes the last step of glycolysis by converting PEP to pyruvate and generating ATP. 
This is the key connection between glycolysis and oxidative phosphorylation. In cancer cells, 
PKM2 dimer with reduced pyruvate kinase activity holds glycolysis at the last step, and 
facilitates the synthesis of intermediate metabolites for the need of proliferation. This is why 
cancer cells develop the mechanism of alternative splicing to produce PKM2 over PKM1 in 
favor of its metabolism (Mazurek, 2011).  
In addition to the metabolic shifting role of PKM2 in the Warburg effect, PKM2 
possesses an important relationship with HIF-1 and c-Myc which are two critical proteins in 
metabolism pathway. PKM2 interacts with HIF-1α subunit and promotes activation of HIF-1 
targeted genes. PHD3 enhances the interaction between PKM2 and HIF-1α. This indicates a 
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positive feedback loop of PKM2 promoting HIF-1 transactivation and regulating metabolism in 
cancer cells (Luo & Semenza, 2011). c-Myc was found to be the key regulator for the shift from 
PKM1 to PKM2 in cancer cells. c-Myc upregulates the transcription of hnRNPA1 and hnRNPA2 
to bind more to exon 9 (PKM1) in order to include exon 10 (PKM2) in the splicing result, thus 
high PKM2/PKM1 ratio (David et al., 2010).  
The study of PKM2 was focused in cytosol as a pyruvate kinase to regulate metabolism 
or in cell nucleus as a protein kinase to promote proliferation. Extracellular PKM2 was 
considered as diagnostic marker for diseases without any specific physiological or pathological 
functions. Serum PKM2 level is used as diagnostic marker in several cancer cases, including 
colorectal cancer, kidney cancer, gastric cancer, lung cancer, and cervical tumors. Our laboratory 
discovered that extracellular PKM2 secreted by cancer cells promoted angiogenesis through 
activation of integrin αvβ3 on endothelial cells. We also found PKM2 located extracellularly at 
cutaneous wound site and in liver fibrosis. Neutrophil is another source of extracellular PKM2 in 
addition to cancer cells. PKM2 was detected from blood circulation and stool samples in several 
immune diseases, but the secretory pathway was not clear. PKM2 secretion is related with 
exosome in cancer cells. In immune diseases, extracellular PKM2 was thought to be released by 
dead immune cells. We discovered that PKM2 was released from activated neutrophils via 
degranulation. Whether PKM2 is located in granules is still need to be examined. 
In wound repair, macrophage is the dominant origin of secreting growth factors and 
cytokines to activate angiogenesis and granulation tissue formation. Macrophages can influence 
each phase of angiogenesis, including ECM rearrangement, endothelial cell proliferation and 
migration, and capillary differentiation. TGFβ secreted from macrophage is considered the main 
activator for myofibroblast differentiation. The classical concept of the connection between 
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inflammation and proliferation stage is that neutrophils come first for cleaning, then 
macrophages arrive later to finish cleaning and promote angiogenesis and granulation tissue 
formation. We found that extracellular PKM2 released from neutrophils facilitated cutaneous 
wound healing by promoting angiogenesis and fibrogenesis. This provides another aspect in 
addition to the conception of macrophage activating proliferation stage. Neutrophils are 
considered the early initiator of angiogenesis and fibrogenesis during wound repair. However, 
extracellular PKM2 activated endothelial cell and fibroblast through integrin αvβ3, which is only 
expressed after activation by TGFβ. It is not feasible for extracellular PKM2 from neutrophils to 
activate angiogenesis and fibrogenesis before TGFβ from macrophages. Another possibility is 
that small amounts of TGFβ are released from platelets early in wound repair and partially 
activate endothelial cells and dermal fibroblasts. Large amounts of PKM2 released during 
neutrophil infiltration enhance the activation and then together with TGFβ from macrophages to 
further augment angiogenesis and fibrogenesis. 
Given the fact that PKM2 is released from neutrophils, a key question is whether the 
released PKM2 is dimer as released from cancer cells. Our lab previously demonstrated that 
PKM2 translocates into cell nucleus and acts as a protein kinase to regulate gene transcription. 
PKM2 dimer functions as a protein kinase, while the tetramer is a pyruvate kinase (Gao et al., 
2012). PKM2 is released from cancer cells and promotes angiogenesis. The released PKM2 is in 
dimeric conformation and shows low pyruvate kinase activity compared with PKM1. The 
dimer/tetramer ratio of PKM2 is also correlated with protein concentration (L. Li et al., 2014). In 
cancer cells, the pathway of PKM2 release is still not well understood. Our preliminary data 
indicated that the release of PKM2 is involved in the secretion of exosome and microvesicle. In 
part two of this dissertation, we discovered PKM2 is released from neutrophil through 
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degranulation, which is a similar secretory pathway as in exosome and microvesicle. Several 
other reports revealed that PKM2 exists in the dimeric conformation upon different 
modifications and mutations (Mazurek, 2007; Stetak et al., 2007). Therefore, we suspect the 
released PKM2 from neutrophils is also in dimeric conformation. The cytosolic PKM2 should 
still be tetramer. After modification such as phosphorylation or binding with other proteins, 
PKM2 may dissociate from tetramer to dimer and further interact with the vesicle or granule 
components during release.  
In this dissertation, we revealed that PKM2 activated FAK-PI3K-PAK2 pathway through 
integrin αvβ3 in dermal fibroblasts and leads to myofibroblast differentiation. This signal 
pathway is independent of TGFβ-Smad pathway. Several factors have been shown to activate 
myofibroblast differentiation without besides TGFβ, such as IL-6, NGF, Fizz1, angiotensin-II, 
endothelin-1, and thrombin. However, the effect of TGFβ is not ruled out in those studies. We 
used TGFβ antibody to neutralize TGFβ residue and TGFβ receptor antibody to inhibit TGFβ 
signal pathway. rPKM2 still can induce expression of α-SMA in the previous two treatments. 
This is a novel signal pathway of myofibroblast differentiation in addition to the classic TGFβ 
one. Extracellular PKM2 can augment the TGFβ effect or even act alone when TGFβ is absence. 
On the pathological side, we claimed that extracellular PKM2 released from activated 
neutrophils protected activated HSCs from apoptosis that results in progression of liver fibrosis. 
In HSCs, extracellular PKM2 activated PI3K signal pathway to stimulate the survival signal. 
Currently, no effective treatment of reversing liver fibrosis/cirrhosis has been found. Most 
studies are focused on the apoptosis of activated HSCs. Our results showed that specific PKM2 
antibody that disrupts the PKM2-αvβ3 interaction is very effective in relieve liver fibrosis in 
TAA/alcohol induced mouse model, indicating a potential anti-fibrosis strategy and target. 
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Compared to fibrosis in liver, the fibrosis progression is very similar in other tissue such as lung 
and kidney. In the future study, we should test the function of extracellular PKM2 in other 
fibrosis models.  
6.5 Conclusions and Future Perspectives  
In summary, extracellular PKM2 shares the same membrane target integrin αvβ3 on 
different cell types and leads to different downstream pathways favoring to the function of cells. 
As the similar proliferating function of nuclear PKM2 in cancer cells, extracellular PKM2 plays 
a similar role of regeneration (angiogenesis and fibrogenesis) in wound healing. Extracellular 
PKM2 acts as a cytokine or growth factor to activate endothelial cells and fibroblasts in favors of 
regeneration. Release of PKM2 from activated neutrophils reveals the connection between 
neutrophil infiltration and tissue regeneration. Nevertheless, in the pathological condition of 
tissue regeneration, extracellular PKM2 acts as a double-edged sword. For example, when you 
have an injury in liver, regeneration of liver undergoes the similar procedure as in the cutaneous 
wound repair. Extracellular PKM2 functions as a supporter to heal injury. If injury persists, 
chronic damage of the tissue leads to continuously influx of neutrophils to the injury site. 
Accumulation of extracellular PKM2 becomes a destroyer by protecting HSCs from apoptosis. 
Therefore, targeting extracellular PKM2 during liver fibrosis can be a valid method of pushing 
HSCs to apoptosis, and finally reversing of liver fibrosis.  
Currently, the study of PKM2 is divided into three parts. First, the canonical function of 
PKM2 is to regulate metabolism in highly proliferating cells. Dimeric PKM2 catalyzes the last 
step of glycolysis with rate limitation. Binding with FBP converts PKM2 to tetramer, and 
enhances the pyruvate kinase activity of PKM2. The balance between PKM2 dimer and tetramer 
is dynamically regulated (Dombrauckas et al., 2005). In cancer cells, to favor proliferation, the 
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balance is more toward to dimeric PKM2 as a result of different modifications, including 
phosphorylation of tyrosine 105 by tyrosine kinase, acetylation of lysine 305 by glucose 
stimulation, and oxidation of cysteine 358 by ROS insult (Hitosugi et al., 2009; Lv et al., 2011). 
The transition from tetramer to dimer PKM2 leads to an increased accumulation of metabolic 
intermediates which support the proliferation of cancer cells. In order to inhibit cancer cell 
proliferation and tumor growth, researchers aim on the discovery of PKM2 activator to drive the 
conversion back to tetrameric PKM2. FBP and serine are the known allosteric activator of 
PKM2. Succinyl-5-aminoimidazole-4-carboxamide-1-ribose-5’-phosphate (SAICAR) also 
regulates PKM2 allosterically (Keller et al., 2012). Two small molecules were identified in a 
screen for PKM2 activator, thieno[3,2-b]pyridazinone (TEEP-46) and N,N’-diarylsulfonamide 
(DASA-58). These to molecules functions similar to FBP to significantly increase the pyruvate 
kinase activity of PKM2. They stabilize PKM2 in a tetramer conformation even with key residue 
mutation such as K305 (Anastasiou et al., 2012).   
Second, in addition to the original role of regulating glycolysis in cytosol, PKM2 
translocates into the nucleus and functions as a protein kinase to promote cancer cell 
proliferation. PKM2 can phosphorylate several protein substrates by using PEP or ATP as the 
phosphate donor. The possible protein substrates include histone H3 on T11, STAT3 on Y705, 
MLC2 on Y118, Bub3 on Y207, and ERK1 on T202. However, the molecular mechanism of this 
protein kinase activity is still not clear. The function of nuclear PKM2 is involved with gene 
expression and cell cycle progression. Nuclear PKM2 interacts with β-catenin and enhances the 
transactivation activity of β-catenin to assist the phosphorylation of histone H3 by PKM2 (W. 
Yang et al., 2011). PKM2 interacts with Oct4 and reduces the transcription activity of Oct4 
which leads to the differentiation of glioma spheroids (Morfouace et al., 2014). PKM2 is also 
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involved in cell cycle and cytokinesis. PKM2 regulates G1-S phase transition by phosphorylating 
Bub3. Aurora B can phosphorylate PKM2 on T45 to stimulate the phosphorylation of MLC2 by 
PKM2. This phosphorylation together with Rho-associated protein kinase 2 (ROCK2) mediated 
phosphorylation on S15 are critical in the process of cytokinesis (Jiang et al., 2014).  
Third, PKM2 is found in extracellular space. Cancer patients have high level of PKM2 in 
the blood serum. Serum PKM2 is used as an un-invasive diagnostic marker for cancer diagnosis. 
Our laboratory discovered that the extracellular PKM2 is released from cancer cells. 
Extracellular PKM2 interacts with integrin αvβ3 on the cell surface of endothelial cells and 
promotes adhesion and migration. In this dissertation, we found PKM2 is also released from 
neutrophils during inflammation. Extracellular PKM2 interacts with integrin αvβ3 on the cell 
surface of both endothelial cells and fibroblasts. PKM2 activates integrin αvβ3 signaling 
pathway to stimulate myofibroblast differentiation. Extracellular PKM2 also activates a survival 
signal through integrin αvβ3 to protect activated HSCs from apoptosis and promotes liver 
fibrosis. Overall, the original function of PKM2 is still in cytosol. After different modifications 
or interacting with other factors, PKM2 tetramer converts to dimer, and then translocates into 
nucleus or releases to the extracellular space.  
The function of extracellular PKM2 is not well elucidated. Previously, we only knew that 
it is correlated with tumor growth. In this dissertation, we observed that neutrophils or other 
immune cells could be another source of extracellular PKM2. If we consider extracellular PKM2 
as a cytokine using integrin αvβ3 as the cell surface receptor, then it is a connection between 
neutrophil infiltration and angiogenesis/fibrogenesis. It helps us to better understand the function 
of neutrophils during inflammation. We revealed that extracellular PKM2 promotes 
myofibroblast differentiation independently of TGFβ. It indicates that neutrophil infiltration 
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places a positive role in myofibroblast differentiation. Alternative PKM2- integrin αvβ3 pathway 
can activate fibroblast without the involvement of the classical TGFβ-Smad pathway. 
Extracellular PKM2 plays another important role during liver fibrosis. Everyone tries to find the 
way to reverse liver fibrosis and focuses on activated HSCs as the target. We think extracellular 
PKM2 could be the key modulator in liver fibrosis. Insult induces inflammation and activates 
different immune cells. The activated immune cells release PKM2 and other cytokines to 
promote differentiation of HSCs. PKM2, together with other growth factors, stimulates the 
survival signal of activated HSCs and keeps them at the damaged liver tissue to induce a chronic 
fibrotic status. We generated a specific antibody against PKM2 and tested it for liver fibrosis. 
The fibrotic damage was well reduced and liver condition was partially reversed to the healthy 
condition. The future study of extracellular PKM2 should be focused on its role in fibrogenesis. 
Animal models with different types of tissue fibrosis should be studied to test the effect PKM2 
antibody.  
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SUPPLEMENTARY RESULTS 
PKM2 translocates into cell nucleus and phosphorylates histone H4 
 
 
Recombinant PKM2 used PEP as substrate to phosphorylate histone H4 at Serine 1 in 
vitro. PKM2 translocated into cell nucleus at S and G2 phases which was correlated with histone 
H4S1 phosphorylation. 
 
